

**Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

**Present Title  
And Affiliation:**

Professor of Medicine and Pediatrics  
Director, Clinical Applications Lab  
Center for Cell and Gene Therapy  
Baylor College of Medicine  
Shipping Address:  
1102 Bates Street Suite 1630  
Houston, Texas 77030

**Birth/Citizenship:** April 30, 1952, Whitehead, Northern Ireland  
Citizen of United States and the United Kingdom

**Home Address:** 2210 Golden Pond                      **Telephone:**                      **e-Mail**  
Kingwood, TX 77345                      281-360-3161                      apgee@txch.org

**Office Address/Telephone:** Baylor College of Medicine  
Center for Cell and Gene Therapy  
6621 Fannin Street, MC 3-3320  
Shipping Address: 1102 Bates Avenue  
Suite 1630  
Houston, Texas 77030  
TEL 832/824-4214, FAX 832/825-4668

**Education (undergraduate/graduate degrees with dates):**

B.Sc. (Upper Second Class Honors) in Biological Sciences, University of  
Birmingham, Birmingham, UK; 1973  
Ph.D., University of Edinburgh, Edinburgh, Scotland; Thesis Title: Immunological  
Studies on Whole Body Hyperthermia Treatment for Advanced Cancer; 1977

**Postgraduate Training with Dates:**

Research Scientist, Teaching & Research Center University of Edinburgh Western General Hospital,  
Edinburgh, Scotland; 1978

Visiting Fellow, National Cancer Institute, Laboratory of Immunobiology, Bethesda, MD; 1978-1981

Research Fellow, University of Toronto, Department of Pathology, Division of Experimental Pathology  
Toronto, Canada; 1981-1982

**Academic and Professional Appointments with Dates:**

Assistant Professor (Visiting: 1982-1985) Division of Hematology/ Oncology; Department of Pediatrics,  
University of Florida, Gainesville, FL; 1982-1987

Associate Director for Research; Division of Hematology/Oncology Dept. of Pediatrics; University of  
Florida, Gainesville, FL; 1985-1987

Assistant / Associate Professor; Dept. of Immunology & Medical Microbiology University of Florida,

## **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

Gainesville, FL; 1984-1987

Associate Professor, Division of Hematology/Oncology, Department of Pediatrics, University of Florida, Gainesville; 1987

Senior Scientist (1987-1992), Manager, Research & Development (1991-1992) Immunotherapy Group, Baxter Biotech, Baxter Healthcare Corporation  
Director, Cell Therapy Group  
Director, Flow Cytometric Analysis

Professor of Medicine, Professor of Microbiology & Immunology Division of Transplantation Medicine, Department of Medicine, University of South Carolina, Columbia, South Carolina; 1992-1997  
Director, Cell Processing Facility  
Director, Flow Cytometry Facility.

Associate Clinical Professor, Division of Hematology/Oncology, Dept. of Pediatrics, Medical University of South Carolina, Charleston, South Carolina; 1992-1997

Adjunct Professor, Clemson University, Cooperative Research & Education, Program, Clemson, South Carolina; 1996

Professor of Medicine, Section of Blood & Marrow Transplantation, Department of Hematology, M.D. Anderson Cancer Center, Houston, Texas; 1997-1999.  
Director, Stem Cell Processing Laboratory  
Director, BMT Flow Cytometry Group

Professor of Medicine & Pediatrics, Director cGMP Facilities, Center for Cell & Gene Therapy, Baylor College of Medicine, Houston, Texas; 1999-present.  
Director, GMP Clinical Applications Lab & Flow Cytometry Facility

### **Administrative Responsibilities with Dates**

Chairman, University of Florida Department of Pediatrics' Science Day Committee; 1986-1987

Planning Committee, University of South Carolina, Richland Memorial Hospital, Research Appreciation Day, May 1996, Columbia, South Carolina; 1995-7

Joint Research Committee, University of South Carolina, Richland Memorial Hospital, Columbia, South Carolina; 1995-7

Administrative Medical Committee, Richland Memorial Hospital Columbia, South Carolina; 1995-7

Bone Marrow Transplant Patient Care Committee, Richland Memorial Hospital, Columbia, South Carolina; 1995-7

Transfusion Task Force, University of Texas MD Anderson Cancer Center, Houston 1997-1999.

Strategic Planning Committee, Center for Cell & Gene Therapy, Baylor College of Medicine 1999-Present.

Member, Clinical Research Oversight Committee, Texas Children's Hospital 2000-present

### **Local, State, National, International Committees (with dates):**

**Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

Board Member, Florida State Board & Local Chapter, Stop Children's Cancer - a registered charity; 1984

Organizer, First International Workshop on Bone Marrow Purging, Orlando, FL; 1987

Co-Organizer, Second International Workshop on Bone Marrow Purging & Processing, Cancun, Mexico; 1989

Co-Organizer, Third International Workshop on Bone Marrow Purging & Processing, San Diego, California; 1991

Member, Advisory Committee for Bone Marrow Transplantation to the American Association of Blood Banks; 1992

Founder, International Society for Hematotherapy and Graft Engineering, ISHAGE; 1992

Co-Founder and Member of the Board of Directors, International Society for Hematotherapy & Graft Engineering, Inc. (ISHAGE); Washington, DC; 1992-1996

Co-Organizer with Dr. Anthony Ho, "Recent Advances in Hematopoietic Stem Cell Transplantation - Clinical Progress, New Technologies and Gene Therapy"; March 11 - 13, 1993, San Diego, California

Co-Organizer, Fourth International Workshop on Bone Marrow Purging & Processing and the First International Meeting of the International Society for Hematotherapy and Graft Engineering (ISHAGE); September 1993, Orlando, FL

Co-Organizer Two Workshops on "Multidimensional Flow Cytometric Analysis of Bone Marrow and Peripheral Blood Stem Cell Preparations." San Jose, California; March 9-10 - November 15-16, 1993; Co-Organizer: Dr. Leon Terstappen.

Member of the North American Task Force for the Development of Standards for Hematopoietic Cell Processing & Transplantation; 1995-Present

Co-Organizer with Dr. Anthony Ho, "Recent Advances in Hematopoietic Stem Cell Transplantation - Clinical Progress, New Technologies and Gene Therapy," San Diego, California; 1995

Co-Organizer, The Second Meeting of the International Society for Hematotherapy and Graft Engineering (ISHAGE), Vancouver, Canada; 1995

Member, Steering Committee, T Cell Depletion Trial, National Heart, Lung & Blood Institute, Bethesda, Maryland; 1995

Member, Board of Directors, Canadian Bone Marrow Transplant Group; 1995-1996

Organizing Committee, "Recent Advances in Hematopoietic Stem Cell Transplantation - Clinical Progress, New Technologies and Gene Therapy," San Diego, California; 1997

Member, Progenitor Cell Standards Task Force American Association of Blood Banks Bethesda, Maryland; 1996

Chair, National Marrow Donor Program Standards Committee, 2001-2002

**Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

Member, Production Assistance for Cellular Therapies Group, 2004

Member, Cellular Therapy Coding and Labeling Advisory Group, 2004-2009

Member, HRSA Advisory Council on Blood Stem Cell Transplantation, 2010

Chair, Review Panel NHLBI SMARTT Program. 2013.

**Editorial Boards:**

Co-Founder, & Co-Editor-in-Chief, *Cytotherapy*, 1999

Founder, & Co-Editor-in-Chief, *Journal of Hematotherapy*, 1992-1998

Regional Editor of *Cancer Research Therapy and Control*

Guest Editor Special Edition of *ImmunoMethods*, Volume 5; Number 3, 1994

**Honors and Awards (partial listing):**

Hastilow Research Scholarship, University of Edinburgh, Scotland; 1973-1977

Selected for 1st International Training Course for Cancer Research Workers run by the International Union Against Cancer; 1974

ICRETT Award by International Union Against Cancer to Study Application of Hyperthermia in the USA; 1977

Young Investigator's Award to present at the 3rd International Symposium on Cancer Therapy by Hyperthermia, Drugs & Radiation; 1980

Lady Tata International Fellowship for Leukemia Res.; 1982-1984

First Prize, University of Florida Dept. of Pediatrics' 1st Annual Science Day; 1983

Wellcome Research Travel Award to visit the Imperial Cancer Research Fund, London, UK; 1984

ICRETT Award by International Union Against Cancer to Study Immunomagnetic Cell Separation; 1984

Wellcome Research Travel Award to visit the Imperial Cancer Research Fund, London, UK; 1986

Scientific Contribution Award from Baxter International; 1991

Fenwal/Immunotherapy Scientific Award; 1992

Leukemia Society of America - Triumphs through Technology Award; 1993

**Society Memberships with Office Held:**

American Society of Blood and Marrow Transplantation (Board member)

American Association for Cancer Research

American Association of Immunologists

## **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

American Society of Hematology  
British Institute for Biology  
British Society for Immunology  
Founder, International Society for Hematotherapy & Graft Engineering (Executive Committee)  
International Society for Experimental Hematology  
Neuroblastoma Society (UK)  
New York Academy of Sciences  
National Marrow Donor Program Standards Committee 1997-; Chair 2001-2002  
Secretary, Board of Directors, Foundation for the Accreditation of Cellular Therapy 1996-2008

### **Grant and Contract Support**

Lady Tata Memorial Trust, London, UK 20,000 pounds sterling; Sensitivity of Leukemia Cells to Complement - A Useful Prognostic Factor 1982-1984

University of Florida, Div. of Sponsored Research \$11,705; Complement Levels in Patients with Leukemia; 1982-1983

American Cancer Society Florida Chapter \$12,000; Elimination of Cancer Cells from Bone Marrow: Acute Lymphoblastic Leukemia as a Model; 1983-1984

National Cancer Institute \$151,000; Elimination of Neuroblastoma Cells from Bone Marrow Using Antibody & Complement; Co-PI; 1983-1986

American Heart Association Florida Chapter \$34,000; The Role of Platelet Factors in Vascular Disease; 1984-1986

American Cancer Society - Institutional Grant \$3,500; Magnetic Purging of T Lymphocytes from Human Bone Marrow; 1984-1985

Pardee Foundation, Midland, Michigan \$100,755; Magnetic Purging of T Lymphocytes from Human Bone Marrow; 1985-1987

American Cancer Society \$134,836; Elimination of Leukemia Cells from Bone Marrow - A Comparative Study of Two Approaches; 1985-1987

American Cancer Society - Florida Chapter \$12,000; The Migration of Hematopoietic Cells from Peripheral Blood into the Bone Marrow Spaces; 1986-1987

American Heart Association Florida Chapter \$228,000 Program Project Grant; The Pathogenesis of Endocarditis - Bacterial Plasmin Receptors; 1986-1988

National Institutes of Health \$180,000; Characterization of the Human TI-2 Response, Co-PI; 1987-1990

National Heart, Lung and Blood Institute \$402,986 (multi-center contract); Therapy Groups to Study T Cell Depletion in Unrelated-Donor Marrow Transplantation; 1993-2001

American Cancer Society \$75,000; Analysis of Marrow Immunomagnetic Purging vs. CellPro Selection in Neuroblastoma, Co-PI; 1994-1995

South Carolina Cancer Center \$24,750; Proposal to Establish Methods for the Evaluation and Manipulation of Hematopoietic Cell Grafts, Co-PI; 1994-1995

## **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

South Carolina Cancer Center \$10,800; Growth Requirements, Characterization, Lineage, and Clinical Implications of Dendritic Cells in Human Bone Marrow Transplants, Co-PI; 1994-1995

South Carolina Cancer Center \$15,000; Development of an Autologous Human Model System to Study Early Events in Hematopoiesis, PI; 1995

South Carolina Cancer Center \$25,000; Development of an Animal Model for Studies on Graft/Host Interactions in Bone Marrow Transplantation, Co-PI; 1994-1995

South Carolina Cancer Center \$15,000; Development of an Autologous Human Model System to Study Early Events in Hematopoiesis, PI; 1995

South Carolina Cancer Center \$25,000; Development of an Animal Model for Studies on Graft/Host Interactions in Bone Marrow Transplantation, Co-PI; 1994-1995

Center for Cancer Treatment & Research \$22,500; Ex Vivo Expansion and Detection of Primitive Human Bone Marrow and Cord Blood Hematopoietic Stem Cells. Co-PI; 1996

Center for Cancer Treatment & Research \$17,307; Generation of Chronic Myelogenous Leukemia-Specific T Cell Clones from Normal Human Blood. PI; 1996

Center for Cancer Treatment & Research \$22,398; Isolation and Subsequent Expansion of Cytomegalovirus Specific Cytotoxic T-Lymphocytes; Co-PI; 1996

South Carolina Cancer Center \$14,731; Isolation and Characterization of Skin Dendritic Cells in Patients Developing Graft Versus Host Disease Following Bone Marrow Transplantation, Co-PI; 1996

Doris Duke Foundation Immunotherapy of Cancer \$293,850; Major goal of this project is to 1) improve hemopoietic stem cell transplantation and the therapy of malignancy, but using adoptive immunotherapy with gene modified effector cells; and 2) support and mentor physician-scientists conducting translational research, Helen Heslop PI; 2000

General Clinical Research Center \$2,611,250; To provide inpatient and outpatient research nursing, dietary, and laboratory support for approved clinical research projects within the Baylor College of Medicine. The center provides this support for both children through Texas Children's Hospital and adults through The Methodist Hospital; Ralph Feigin PI; 2001

Adenoviral Vector Production at Baylor College of Medicine \$329,635; To become a member of the National Gene Vector Laboratory providing production of clinical grade vectors; Malcolm Brenner PI; 2001

Vesta Therapeutics (formerly Incara Pharmaceuticals) \$136,102; Pre-clinical process development and GMP cell processing services to support Vesta Therapeutics human liver precursor cell therapy program. Primary Contractee; 2001

Enhancing T Cell Therapy of Cancer \$1,082,728; Major Goals of Project: 1) increase the anti-tumor efficacy of the CTL; 2) expand the range of applications for which viral specific CTL can be used; and 3) identify the epitopes most readily recognized by the tumor specific CTL so that we can enhance the cellular responsiveness to these targets; Helen Heslop PI; 2002

SAIC-Frederick, Inc. Production of a Clinical Lot of Epstein-Barr Virus (EBV) \$150,649; Supernatant Development of cord blood cells for the tech transfer, wet run. Production for clinical studies pertaining to expansion of cord blood units; Primary Contractee; 2002

## **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

National Marrow Donor Program \$248,578; The overall aim of this study is to prospectively determine the relationship between bone marrow CD34+ and CD3+ cell dose and clinical outcome, using a single immunophenotyping reference laboratory and studying approximately 650 bone marrow transplants at multiple National Marrow Donor Program Transplant Centers over the period of two years; Primary Contractee; 2002

Gamida-Cell, Ltd \$183,385; Scientific development of cord blood cells for the technology. Transfer, wet runs and production for clinical studies pertaining to expansion of cord blood units. Primary Contractee; 2002

Baylor College of Medicine, RP4 Development of RTVP-1 Gene Therapy for Prostate Cancer; 2003

Malcolm Brenner PI; National Heart, Lung & Blood Institute, \$10,591,030; Improving the safety and efficacy of cell therapies; 09/30/2005 - 08/31/2010

Brenner MK and Gee AP MIRA Cellular Therapy of Cancer – RP110553 Cancer Prevention and Research Institute of Texas Clinical Research Core \$6,214,354 07/01/11 – 06/30/16

Gee A.P. Cancer Prevention and Research Institute of Texas. Texas Assistance for Cancer Cell Therapy - \$3,875,000 RP130256 06/01/13 – 05/31/18

Cardiovascular Cell Therapy Research Network – Data Coordinating Center; Quality Assurance Services for Cell Processing Facilities NHLBI 2008-2016

Gee AP PI, Somatic Cell Therapy Processing Facility National Heart, Lung & Blood Institute \$12,000,000; 2010-2015

### **Patents Granted**

Apparatus and Method for Positive Cell Selection USSN: 08/187,419. Device on display in Smithsonian Institution, Washington, DC

### **Teaching Experience**

#### University of Florida

First year medical student immunology (consistently rated as one of top three lecturers)

Development of Patient Oriented Problem Solving (POPS) teaching system for complement and bone marrow transplantation.

Member of PhD committees in Department of Immunology and Medical Microbiology.

#### Baxter Healthcare Corporation

No teaching responsibilities

#### University of South Carolina

No formal teaching responsibilities

Lectured to graduate students in Department of Microbiology and Immunology on ad hoc basis

## **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

Supervised two honors students' theses

Supervised approximately eight South Carolina Cancer Center summer student projects.

Supervised two post-doctoral research fellows, one research associate and one visiting research fellow.

Post-doctoral thesis committee member, University of Texas MD Anderson Cancer Center, 1998

### **Miscellaneous Committees/Consultancies/Professional Activities:**

Invited consultant, University of Maryland Cancer Center, Baltimore, MD; January 4, 1994

Keystone Symposium on Bone Marrow Transplantation, Keystone CO; 1994: Co-Organizer of Workshop on Standardization in Bone Marrow Processing Laboratories

Keynote speaker, Opening of the Bone Marrow Processing Laboratories of the Central Laboratories of the Netherlands Red Cross Regulation and Standardization: Friend or Foe? Amsterdam, The Netherlands; 1995

Invited Consultant, Texas Transplant Institute, San Antonio, Texas 2000-

Invited Consultant, Wake Forest University Bone Marrow Transplant Program, 2002

Invited Consultant, Louisiana State Gene Therapy Initiative, 2003

Invited Consultant, Aurora St. Luke's Medical Center, Milwaukee 2008

Consultant on GMP Facility Design Yale University, New Haven 2010

Consultant on GMP Facility Design Rosemount Hospital, Montreal, Canada 2010

Consultant GMP Facility Design University of Colorado, Denver 2012

Consultant on GMP Facility Design Wisconsin Blood Center, Milwaukee 2013

Consultant on GMP Facility Design NIH Clinical Center, Bethesda 2013

Consultant on GMP Facility Design Roswell Park Memorial Institute, Buffalo 2013

### **Consultancies/Ad Hoc Advisor:**

AmCell

Amgen

Caremark

COBE BCT

Immunicon

Immunotherapy Group, Baxter BioTech, Baxter International

### **Ad Hoc Reviewer:**

American Society of Hematology (abstracts)

Blood

Bone Marrow Transplantation

Cancer Research

Cancer Research, Therapy and Control

Canadian Red Cross Grants



## Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae

Experimental Hematology  
Journal of Immunology  
Journal of Leukocyte Biology  
March of Dimes Grants  
Medical Research Council of Canada Grants  
NIH Study Sections  
UK Medical Research Council Grants  
Victoria State (Australia) Cancer Control Agency Grants  
Science

### **Invited Speaker (partial listing):**

- Chairman, European Neuroblastoma Study Group Meeting, London; 1986
- Leukemia Society of America 3rd Annual Medical Symposium; 1987
- Fine Particle Society Annual Meeting; 1987
- American Society for Cell Biology Workshop on Magnetic Cell Separation; 1987
- American Association of Tissue Banks meeting on Banking Autologous Bone Marrow; 1989
- Johns Hopkins Workshop on Autologous Marrow Processing; 1989 & 1990
- Opening of the Hanson Centre for Cancer Research, Adelaide, Australia; 1990
- John Ugelstad Symposium on Magnetic Separations, Oxford, United Kingdom; 1991
- American Society for Apheresis, Chicago, Illinois; 1992
- American Association of Blood Banks; 1992-1993
- Medical University of South Carolina; 1993 Duke University; 1993
- London Regional Cancer Centre on Peripheral Blood Progenitor Cell Transplantation: Clinical Technical and Economic Considerations, London, Ontario, Canada; 1993
- American Society of Clinical Pathologists Meeting, Atlanta, GA; 1993
- Flow Cytometry Users Groups: Atlanta, GA 1993, Raleigh, NC; 1993
- American Society of Clinical Pathologists Workshop, Atlanta, GA; 1993: "The Impact of Bone Marrow Transplantation in the Clinical Laboratory"
- IBC Conference "The Development of Standards and Guidelines for Hematopoietic Stem Cell Processing", San Diego, CA ; 1994
- AMGEN Workshop for the Evaluation of CD34 Cell Content of Hematopoietic Grafts, Chicago, IL; 1994
- Canadian Bone Marrow Transplant Meeting, Ottawa, Ontario Canada; 1994
- Clemson University, Greenville Memorial Hospital "Hematopoietic Cell Manipulation - the Magic Bullet of the '90s; Greenville, SC; 1994
- Clinical Flow Cytometry Society, Charleston, SC; 1994
- National Heart, Lung and Blood Institute Stem Cell Processing Workshop: General Overview: Practical aspects of purging, Bethesda, MD; 1995
- Beyond the Basics: Updates in Cancer Care Hollings Cancer Research Center Medical University of South Carolina, Charleston, SC; 1995
- John Voigt Memorial Lecture, Walt Disney Cancer Research Center, Orlando, FL; 1995
- The Canadian Red Cross and the Canadian Blood Transfusion Society: Peripheral Blood Progenitor Cell Transplants - The End of BMT? Edmonton, Canada; 1995
- Managing the High Dose/Stem Cell Patient in the Community Setting, Laguna Beach, CA; 1995
- Aastrom Biosciences, Ann Arbor, MI; 1995
- Ten Years of Blood Stem Cell, Transplantation in Heidelberg, Heidelberg, Germany; 1995
- Flow Cytometry Users Meeting, Atlanta, GA; 1995
- Second International Cord Blood, Stem Cell Conference, San Francisco, CA; 1995
- Keystone Symposium on Blood Cell and Bone Marrow Transplants Cell Processing Workshop, Keystone, CO; 1996

### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- Cell Culture and Separations for Cell and Gene Therapies, Positive and Negative Cell Selection, Northwestern University, Evanston, Illinois; June 24-27, 1996
- Canadian Society of Transfusion Medicine, Canadian Red Cross Society Conference; Peripheral Stem Cell Collection and Manipulation, Toronto, Ontario Canada; May 23-26, 1996
- Foundation for the Accreditation of Hematopoietic Cell Therapy Inspector Training Course, Regulation of Hematopoietic Cell Therapy and Application of cGMP, University of Nebraska Medical Center, Omaha, Nebraska; September 9-10, 1996
- American Association of Blood Banks: The History of Regulation of Stem Cells, Orlando, Florida; October, 12-16, 1996
  - American Association of Blood Banks: Positive Selection, Negative Selection and The Search for the Elusive Stem Cell, Orlando, Florida; October, 12-16, 1996
  - T Cell Depletion - Walking the Tight Rope, Cook Fort Worth Children's Hospital, Ft Worth, Texas; November 7, 1996
  - Transplantation and the Food & Drug Administration, Pediatric Bone Marrow Transplantation, Ft. Lauderdale, Florida; January 1997
  - T Cell Depletion Technology Pediatric Bone Marrow Transplantation, Ft. Lauderdale, Florida; January 1997
  - Regulation of Hematopoietic Stem Cell Transplantation: A Blessing or a Curse? CellPro Workshop, European Bone Marrow Transplant Meeting, Aix-les-Bains, France; March 1997
  - Stem Cell Graft Engineering - Regulation without Fossilization, International Symposium on Applications of Flow Cytometry in Stem Cell Transplantation, Atlanta, Georgia; April 1997
  - Graft Engineering - What have we learned? 5<sup>th</sup> International Symposium on Stem Cell Transplantation, San Diego, California; April 1997
  - Regulation of Stem Cell Collection and Processing Peripheral Blood Stem Cells 1997 - A Training Course, Tempe, Arizona; May 1997
  - Cell Culture and Separations for Cell and Gene Therapies, Positive and Negative Cell Selection, Northwestern University, Evanston, Illinois; June 1997
  - Graft Engineering, University of Rochester, New York, July 1997.
  - Regulation of Hematopoietic Stem Cell Transplantation, American Association of Blood Banks, Denver, Colorado, October 1997.
  - Hematopoietic Stem Cell Engineering, American Society of Mechanical Engineers, Dallas, Texas, November 1997.
  - Applications of Flow Cytometry in Stem Cell Transplantation, Becton Dickinson Flow Cytometry User's Group, Houston, Texas, February, 1998
  - Immunophenotypic Monitoring in Transplantation, International Society for Analytical Cytometry, Colorado Springs, Colorado, March 1998.
  - Texas - Does Bigger Always Mean Better? University of South Carolina, April 1998.
  - Current Good Manufacturing Practices - Stem Cells, American Society for Apheresis, St. Petersburg, Florida, May 1998.
  - Symposium on Current Good Manufacturing Practices in Hematopoietic Stem Cell Processing, Tempe, Arizona, April 1999.
  - 41<sup>st</sup> Annual American Society of Hematology, New Orleans, LA, December 1999.
  - Inspection and Accreditation of Cell Processing Laboratories in North America, Joint Accreditation and Inspection Committee in Europe Meeting, Barcelona, Spain, January 2000.
  - Distinguished Visiting Professor, Medical College of Ohio, Toledo Ohio, April 2000.
  - Fort Worth Cook Children's Hematology & Oncology Center, April 2000.
  - American Society of Gene Therapy Clinical and Regulatory Affairs meeting, Denver, CO, June 2000.
  - International Society for Hematotherapy & Graft Engineering, San Diego, California, June 2000.
  - 10<sup>th</sup> International Symposium on Autologous Blood & Marrow Transplantation, July 2000.
  - NMDP Council Meeting, Minneapolis, MN, September 2000.
  - ASME Int'l 13<sup>th</sup> Annual Bioprocess Technology Seminar, San Diego, CA, September 2000.

## **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- AABB Annual Meeting, Washington, DC, November 2000.
- ASH 42<sup>nd</sup> Annual Meeting 2000, San Francisco, CA, December 2000.
- FAHCT Board Meeting, Keystone, CO, February 2001.
- Gene Therapy Vector Production Conference, Bethesda, MD, March 2001.
- Mesenchymal & Nonhematopoietic Stem Cell Conference, New Orleans, LA, March 2001.
- FDA Meeting on Cell Sorting & Flow Cytometry, Baltimore, WA, April, 2001.
- NMDP Standards Committee Mtg, Minneapolis, MN, May 2001.
- ISHAGE 2001 Annual Meeting, Quebec City, Canada, June 2001.
- Bio/Medical Technology Club, Houston, Texas, January 2002.
- American Association of Blood Banks and the Education Department, Audio Conference. Computer Validation in the Cell Therapy Laboratory. February 2003.
- Cell & Tissue BioProcessing Conference. Williamsburg BioProcessing Foundation. Challenges for Multi-Product Academic Cell Processing Facilities. Memphis, Tennessee, September 2003.
- Williamsburg BioProcessing Foundation's 6<sup>th</sup> Annual Conference on Facilities for Mammalian Cell Products. Manufacturing Cell Products in an Academic Facility. Coronado, California, October 2003.
- International Society of Cellular Therapy Annual Meeting. Development & Implementation of an Environmental Cleaning & Monitoring System in an Academic GMP Cell Therapy Facility. May 2004.
- International Society of Cellular Therapy Annual Meeting. Cellular Therapy. Another false start? May 2004.
- Phacilitate Cell & Gene Therapy Forum 2005. Current Impediments to the Development of Gene Therapy Products. January 2005.
- Christian Medical College, India. GMP and GTP in Cell Therapy – When and What and the Regulatory Approach in the United States. June 2005.
- JACIE, Greece. Inspectors Course. September 2005.
- Universita Milano Bicocca, Italy. Manufacturing & Testing Cell Therapy Products in an Academic Facility. October 2005.
- BioProcessing Technology Institute, Singapore. Regulation of Cellular Therapy in the United States and Operation of a GMP/GTP Cellular Therapy Facility in an Academic Center. November 2005.
- University of Alabama, Birmingham, AL. Challenges in Cell and Gene Therapy Product Manufacturing in the Academic Environment. April 2007.
- McGowan Institute of University of Pittsburgh, Pittsburgh, PA. Cell Therapy Trials: the Baylor Pipeline. March 2008.
- University of Toledo, Toledo, OH. The Rebirth of Cell 7 Gene Therapy. May 2009.
- Canadian Stem Cell Network, Montreal, Canada. Getting ready for PACT. April 2010.
- Drug Information Association, Bethesda, MD. Clinical Development of Stem Cell Therapies: Scientific, Regulatory and ethical Considerations. April 2010.
- Association of Clinical Research Professionals, Tampa, FL. Cell Therapy Research: Challenges of NIH Network Trials. April 2010.
- American Society of Gene & Cell Therapy, Washington DC. Reporting on unused products and facility issues in response to Dear Cell and Gene Therapy IND Holder issues. May 2010.
- International Society of Cell Therapy, Philadelphia, PA. Use of the Sepax in Cardiovascular Regenerative Medicine - The CCTRN Experience. May 2010.
- Engineering Conferences International – Scale-up and Manufacturing of Cell-Based Therapies II. San Diego – Invited speaker. Manufacturing Cellular Products for Phase I Trials. January 2013
- International Society of Cellular Therapy. Auckland, New Zealand – Invited speaker. How to Run a Large GMP Facility, and Recalls and Returns. April 2013.

## **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- Cardiovascular Cell Therapy Network Steering Committee Meeting, Houston, Texas–Invited speaker. CCTRN-1 Cardiovascular Stem Cell Trials – March 2013
- HRSA Advisory Council on Blood Stem Cell Transplantation – Invited Speaker. Non-Hematopoietic Applications for “Stem Cells”. September 2013
- NHLBI Symposium on Stem Cell Derived Products for Transfusion, Bethesda – Invited speaker. Improving the Utility of Pluripotent Cells for GMP Blood Cell Production, October 2013
- Production Assistance for Cellular Therapy Webinar – Invited speaker. Cellular Therapy: Clinical Research Roadmap. November 2013.

### **Academic Activity**

Member, National Marrow Donor Program, Standards Committee, Minneapolis, Minnesota; 1997-Present

Chair, National Marrow Donor Program, Standards Committee, Minneapolis, Minnesota; 2001-2002.

Member, Regulatory Affairs Committee, American Society for Gene Therapy, 2000-present.

Secretary, Foundation for the Accreditation of Hematopoietic Cell Therapy (FAHCT), Board of Directors, Omaha, Nebraska; 1996-2008

Member, Board of Directors, and Clinical Affairs Committee, American Society for Blood and Marrow Transplantation; 1996-8

Member, Executive Committee, International Society for Hematotherapy and Graft Engineering; 1996-2008

Co-Organizer, ISHAGE Good Manufacturing Practices Workshop, Tempe, AZ, April 1999

Founder and Co-editor in chief, Journal of Hematotherapy, 1992-1999.

Co-Founder & Co-Editor in Chief, Cytotherapy; 1999

Consultant in GMP Cell Processing Facility, University of Texas Southwestern Medical Center, Dallas, 1999

Co-Chair Plenary Session American Society of Hematology Meeting, San Diego, California, 1997; Miami Beach, Florida, 1998; New Orleans, Louisiana, 1999, Philadelphia, Pennsylvania 2001

Moderator. Hematopoietic Progenitor Cell Recruitment and Mobilization. 44<sup>th</sup> Annual Meeting of the American Society of Hematology, Philadelphia, Pennsylvania, December 2002.

Expert Panel Member. National Heart, Lung and Blood Institute, Trans-Divisional Working Group for Specialized Center of Clinically Oriented Research (SCCOR), Washington, DC, June 2003.

Member, Clinical Development Advisory Council, California Institute for Regenerative Medicine. San Francisco February 2014.

### **Research Interests:**

- Bone Marrow Transplantation
- Cell Separation Technology
- Hematopoiesis & Graft Engineering
- Complement

## **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

### **Commercial Experience:**

- Establishment & equipping of research laboratories and clinical laboratory testing and graft engineering facilities
- Direction of research activities of Hematotherapy project group (working on 5 large multi-center projects)
- Development of purging systems for three diseases (neuroblastoma, breast cancer & non-Hodgkin's lymphoma), and of a stem cell collection procedure.
- Development of procedures for the evaluation and QA/QC of monoclonal antibodies
- Development of model systems for bone marrow purging & hematopoietic progenitor cell enrichment
- Design and implementation of project plans and quality leadership procedures
- Writing clinical protocols and regulatory materials and interacting with product labeling and packaging groups
- Management of seven external consultants at major medical & research centers and of various research grants and contracts
- Presentation of project plans and reports to in-house committees and external divisional and corporate scientific advisory boards
- Development and coordination of a training course for European sales force
- Conduct due-diligence evaluations
- Coordination of project plans with engineering, organic chemistry, antibody manufacturing and engineering project groups
- Chair space and facilities planning committee

### **Last Commercial Performance Evaluation:**

Baxter Healthcare Corporation April, 1992 - Grade: Distinguished Definition: "This rating is reserved for those who clearly and consistently demonstrate extraordinary and exceptional accomplishment in all major areas of responsibility. Others who hold positions of comparable scope and responsibility rarely equal performance of this caliber. Those who perform at this level are easily recognized by others outside their own group or division."

### **Published Articles in Refereed Journals:**

- 1) **Gee AP**, Borsos T, Boyle MDP: Interaction between components of the human classical complement pathway and immobilized Cibacron Blue F3GA. J Immunol Methods. 30:119-126, 1979.
- 2) Boyle MDP, **Gee AP**, Borsos T: Studies on the terminal stages of immune hemolysis. VI: Osmotic blockers of differing Stokes' radii detect complement-induced channels of differing size. J Immunol. 123:77-82.
- 3) **Gee AP**, Boyle MDP, Langone JJ: Effect of Concanavalin A on the hemolytic activity of components of the complement pathway. Mol Immunol 17:143-146, 1980.
- 4) **Gee AP**, Boyle MDP, Borsos T: Distinction between C8 and C8/C9-mediated hemolysis on the basis of independent Rb and hemoglobin release. J Immunol 124:1905-1910, 1980.
- 5) Boyle MDP, **Gee AP**, Okada M, Borsos T: Differences in cell-bound C8 sites on chicken erythrocytes measured by their reactivity with guinea pig and human C9. J Immunol 125:2818-2822, 1980.
- 6) **Gee AP**, Boyle MDP, Borsos T: Differences in functional activity of human and guinea pig C1

### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- based on their reactivity with IgG at low temperature. Mol Immunol 18:609-613, 1981
- 7) Boyle MDP, **Gee AP**, Borsos T: Heterogeneity in the size and stability of transmembrane channels produced by whole complement. Clin Immunol Immunopath 20:287-295, 1981.
  - 8) **Gee AP**, Langone JJ: Immunoassay using Iodine<sup>125</sup> or enzyme-labeled Protein A and antigen-coated tubes. Anal Biochem 116:524-530, 1981.
  - 9) **Gee AP**, Boyle MDP, Munger KL, Lawman MJP, Young M: Nerve growth factor: Stimulation of polymorphonuclear leukocyte chemotaxis *in vitro*. Proc Natl Academy of Sciences USA, Cell Biol 2 (Dec) 80:7215-7218, 1983.
  - 10) Lawman MJP, Boyle MDP, **Gee AP**, Young M: A rapid technique for measuring leukocyte chemotaxis *in vivo*. J Immunol Methods 69:197-206, 1984.
  - 11) Graham-Pole J, **Gee AP**: Cancer treatment using autologous bone marrow infusions. J Fla Med Assoc 71:336-343, 1984.
  - 12) **Gee AP**: Advantages and limitations of methods for measuring cellular chemotaxis and chemokinesis. Mol Cell Biochem 62:5-11, 1984.
  - 13) **Gee AP**, Minta JO: Migration of porcine endothelial and smooth muscle cells in response to platelet-associated factors. Am J Hematol 17:29-38, 1984.
  - 14) **Gee AP**, van Hilten J, Graham-Pole J, Boyle MDP: Antibody-complement killing of neuroblastoma cells. Advances in Neuroblastoma Research. Progress in Clinical and Biological Res 175/471-484, 1985.
  - 15) Boyle MDP, Lawman MJP, **Gee AP**, Young M: Nerve growth factor: A chemotactic factor for polymorphonuclear leukocytes *in vivo*. J Immunol 134: 564-568, 1985.
  - 16) **Gee AP**, Rolfe AE, Worthington-White D, Graham-Pole J, Boyle MDP: A rapid alternative to the clonogenic assay for measuring antibody and complement-mediated killing of tumor cells. Clin Immunol Immunopathol 34:263-271, 1985.
  - 17) Young M, **Gee AP**, Boyle MDP, Lawman MJP, Munger KL: Nerve growth factor: A structural relationship between its proteolytic and leukocyte-chemotactic active sites. Mol Cell Biochem 66:65-69, 1985.
  - 18) **Gee AP**, Bruce KM, Morris TD, Boyle MDP: Evidence for an anti-complementary factor associated with human bone marrow cells. J Natl Cancer Inst 75:441-445, 1985.
  - 19) Lawman JP, Boyle MDP, **Gee AP**, Young M: Nerve growth factor accelerates the early cellular events associated with wound healing. Experimental and Molecular Pathology 43: 274-281, 1985.
  - 20) Boyle MDP, **Gee AP**: Low antigen density tumor cells - An obstacle to effective autologous bone marrow purging? Cancer Investigation. 5:113-118, 1987.
  - 21) **Gee AP**, Bruce KM, van Hilten J, Siden EJ, Braylan RC, Bauer PC, Boyle MDP: Selective loss of expression of a tumor-associated antigen on a human leukemia cell line induced by treatment with monoclonal antibody and complement, J Nat Cancer Inst 78: 25-29, 1987.

**Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- 22) Boyle MDP, Chiodo VA, Lawman MJP, **Gee AP**, Young M: Urokinase: A chemotactic factor for polymorphonuclear leukocytes *in vivo*. J Immunol 139: 169-174, 1987.
- 23) **Gee AP**, Lee C, Bruce K, et al. Immunomagnetic purging and autologous transplantation in Stage D neuroblastoma. Bone Marrow Transplantation 2, Suppl. 2, 89-93, 1987.
- 24) **Gee AP**, Lee C, Sleasman JW, Madden M, Ugelstad J, Barrett DJ: T lymphocyte depletion of human peripheral blood and bone marrow using monoclonal antibodies and magnetic microspheres. Bone Marrow Transplantation 2:155-163, 1987.
- 25) Kemshead JT, Treleaven J, Heath L, O'Mara A, **Gee AP**, Ugelstad J: Monoclonal antibodies and magnetic microspheres for the depletion of leukemic cells from bone marrow harvested from autologous transplantation. Bone Marrow Transplantation 2:133, 1987.
- 26) Mehta P, Lawson D, Ward MB, Kimura A, **Gee AP**: Effect of human tumor cells on platelet aggregation: Potential relevance to pattern of metastasis. Cancer Research 47: 3115-3117, 1987.
- 27) **Gee AP**, and Boyle, M.D.P.: Purging tumor cells from bone marrow by use of antibody and complement - a critical appraisal. Journal of the National Cancer Institute. 80: 154, 1988.
- 28) Janssen WE, Munger KL, **Gee AP**: The migration of hematopoietic cells: an in vitro study system. Leukemia 2, pp. 307-312, 1988.
- 29) Griebel PJ, Qualtiere L, Davis WC, **Gee AP**, Bielefeldt H, et al: T lymphocyte population dynamics and function following a primary bovine Herpesvirus Type-1 infection. Viral Immunol 1, p. 287, 1987/8.
- 30) Saleh RA, Gross S, Cassano W, **Gee AP**: Metastatic retinoblastoma successfully treated with immunomagnetic purged autologous bone marrow transplantation. Cancer 62, 2301, 1988.
- 31) Griebel PJ, **Gee AP**: Qualtiere, L. et al: Negative enrichment of bovine T lymphocytes with monoclonal antibodies and magnetic microspheres. Veterinary Immunol & Immunopathol 22, pp.166-173, 1989.
- 32) **Gee AP**, Mansour V, Weiler M: T cell depletion of human bone marrow. J Immunogenetics 16:103-115, 1989.
- 33) Janssen WE, Lee C, Gross S, **Gee AP**,: Low antigen density leukemia cells: Selection and comparative resistance to antibody-mediated marrow purging. Experimental Hematology 17, 252, 1989.
- 34) Graham-Pole J, **Gee AP**, Janssen W, Lee C, Gross S: Immunomagnetic purging of bone marrow a model for negative cell selection. Am J Pediatr Hematol Oncol 12, 257, 1990.
- 35) Galileo DS, **Gee AP**, Linser PJ: Neurons are replenished in cultures of embryonic chick optic tectum after immunomagnetic depletion. Developmental Biol 146, 278, 1991.
- 36) **Gee AP**, Mansour VH, Weiler MB: Effects of target antigen density on the efficacy of immunomagnetic cell separation. J Immunol Methods 142, 127, 1991.
- 37) Graham-Pole J, Casper J, Eifenbein G, **Gee AP**, et al: High-dose chemoradiotherapy supported

### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- by marrow infusions for advanced neuroblastoma. J Clin Oncol 9, 152, 1991
- 38) Graham-Pole J, **Gee AP**, Emerson S, et al: Myeloablative chemoradiotherapy & autologous bone marrow infusions for treatment of neuroblastoma: Factors influencing engraftment. Blood 78, 1607, 1991
  - 39) Chang Y, **Gee AP**, Smith A, Lake W: Activating hydroxyl groups of polymeric carriers using 4-fluorobenzenesulfonyl chloride. Bioconjugate Chemistry 3:200,1992.
  - 40) Cairo MS, Law P, van den Ven C, Plunkett JM, Williams D, Ishizawa L, **Gee AP**: The *in vitro* effects of stem cell factor and PIXY 321 on myeloid progenitor formation (CFU-GM) from immunomagnetic separated CD34+ cord blood. Pediatric Research 32:277, 1992.
  - 41) **Gee AP**: Tumor cell purging and positive selection of hematopoietic stem cells. J Clinical Apheresis, 73:135-137, 1992.
  - 42) Moss TJ, Xu ZJ, Mansour VH, Hardwick A, Kulcinski D, Ishizawa L, Law P, **Gee AP**: Quantitation of tumor cell removal from bone marrow: a preclinical model. J Hematotherapy 1:65, 1992.
  - 43) Patel K, Frost G, Rossell R, Pizer B, **Gee AP**, Sugimoto T, Phimister E, Kemshead J: Expression of the neural cell adhesion molecule (NCAM) on the haemopoietic cell line Nalm-16. Leukemia Research 16(3):307, 1992.
  - 44) Preti RA, Collins NH, **Gee AP**: ISHAGE bone marrow processing survey: Preliminary analysis of an international information gathering process. J Hematotherapy 2:103, 1993.
  - 45) Ishizawa L, Hangoc G, Van De Ven C, Cairo M, Burgess J, Mansour V, **Gee AP**, Hardwick C, Traycoff C, Srour E, Hoffman R, Law P: Immunomagnetic Separation of CD34+ Cells from Human Bone Marrow, Cord Blood and Mobilized Peripheral Blood. J Hematotherapy 2:3, 329, 1993.
  - 46) **Gee AP**: Preparation of Samples for Flow Cytometric Analysis. J Hematotherapy 2:3, 413, 1993.
  - 47) Law P, Ishizawa L, van de Ven C, Burgess J, Hardwick A, Plunkett M, **Gee AP**, Cairo M: Immunomagnetic positive selection and colony culture of CD34+ cells from blood. J Hematother 1993 Summer; 2(2):247-50, 1993.
  - 48) Lee C, Brouillette M, Lamb L, Pati A, Brown S, Thompson J, Parrish R, Henslee-Downey PJ, **Gee AP**: Use of a closed system for V alpha beta-positive T cell depletion of marrow for use in partially mismatched related donor (PMRD) transplantation. Prog Clin Biol Res 389:523-32, 1994.
  - 49) Shpall EJ, Gehling U, Cagnoni P, Purdy M, Hami L, **Gee AP**: Isolation of CD34-positive Hematopoietic Progenitor Cells. ImmunoMethods 5:197-203, 1994.
  - 50) **Gee AP**: Immunologically-based Methods for the Elimination of Tumor Cells from Autologous Bone Marrow Grafts. ImmunoMethods 5:232-242, 1994.
  - 51) Laver J, Traycoff C M, Abdel-Mageed A, **Gee AP**, Lee C, Turner C, Srour E F, Abboud M: Effects of CD34+ Positive Selection and T Cell Immunodepletion on Cord Blood Hematopoietic Progenitors: Relevance to Stem Cell Transplantation. Experimental Hematology 23:1492-1496,1995.
  - 52) Lamb LS, Szafer F, Henslee-Downey, PJ, Walker M, King S, Godder K, Pati AR, Best R,



### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- Steinman L, **Gee AP**: Characterization of Acute Bone Marrow Graft Rejection in T-Cell Depleted Partially Mismatched Related Donor Bone Marrow Transplantation. Experimental Hematology 23:1596-1600,1995.
- 53) Pati A, Godder K, Lamb L, **Gee AP**, Henslee-Downey PJ: Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplantation 15:979-981, 1995.
- 54) Lamb L, Lee C, **Gee AP**, Geier S, Harris G, Parrish R, Walker M, Silverman D, Godder K, Pati A, Henslee-Downey PJ: Patterns of acute rejection following transplantation of partially matched bone marrow. Bone Marrow Transplantation 17:1021-1027, 1996.
- 55) Godder K, Pati A, Abhyankar S, **Gee AP**, Parrish R, Lee C, Henslee-Downey PJ: Partially mismatched related donor transplants as salvage therapy for patients with refractory leukemia who relapse post-BMT. Bone Marrow Transplantation 17:59-53, 1996.
- 56) Civin CI, Trischmann T, Kadan NS, Davis J, Noga S, Cohen K, Duffy B, Groenewegen I, Wiley J, Law P, Hardwick A, Oldham F, **Gee AP**: Highly Purified CD34-Positive Cells Reconstitute Hematopoiesis. J Clin Oncology 14:2224-2233, 1996.
- 57) Ye Z, **Gee AP**, Bowers WE, Lamb LS, Turner MW, Henslee-Downey PJ: In vitro expansion and characterization of dendritic cells derived from human bone marrow CD34+ cells. Bone Marrow Transplantation 18:997-1008, 1996.
- 58) Pati AR, Godder KT, Abhyankar SH, **Gee AP**, Henslee-Downey PJ: Cyclosporine-induced autologous graft-versus-host-disease following autologous blood stem cell transplantation for lymphoma. Bone Marrow Transplantation 17:1081-1083, 1996.
- 59) Lamb LS Jr, Henslee-Downey PJ, Parrish RS, Godder K, Thompson J, Lee C, **Gee AP**: Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother Oct;5(5):503-9, 1996.
- 57) **Gee AP**: Regulation of Hematopoietic Stem Cell Transplantation - An Evolving Policy. Chimera 1996.
- 58) Henslee-Downey PJ, Abhyankar MD, Parrish R, Pati AR, Godder KT, Neglia WJ, Goon-Johnson KS, Geier SS, Lee CG, **Gee AP**. Use of Partially Mismatched Related Donors Extends Access to Allogeneic Marrow Transplant, Blood 89(10)pp3864-3872, 1997.
- 59) Lamb LS Jr, Robbins NF, Abhyankar S, Joyce M, Stetler-Stevenson M, Henslee-Downey PJ, **Gee AP**: Flow cytometric cell sorting combined with molecular chimerism analysis to detect minimal recurrent leukemia: good news and bad news. Bone Marrow Transplant, Jun;19(11)1157-61, 1997.
- 60) Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, **Gee A**, Champlin R. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies, J Clin Oncol Aug;16(8):2817-24, 1998.
- 61) Lamb LS Jr, **Gee AP**, Henslee-Downey PJ, Geier SS, hazlett L, Pati AR, Godder K, Abhyankar

### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- SA, Turner MW, Lee C, Harris WG, Parrish RS: Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donors. Bone Marrow Transplant, Mar;21(5):461-471, 1998.
- 62) Godder KT, Abhyankar SH, Lamb LS, Best RG, Geier SS, Pati AR, **Gee AP**, Henslee-Downey PJ. Donor leukocyte infusion for treatment of graft rejection post partially mismatched related donor bone marrow transplant. Bone Marrow Transplant, Jul;22(1):111-3, 1998.
- 63) Przepiorka D, Lu J-G, Anderlini P, Korbling M, Donato M, Champlin R, **Gee AP** and Vlasselaer, P van. Debulking blood stem cell collections by density gradient centrifugation in a closed-vessel system, Cytotherapy 1(2)pp111-117, 1999.
- 64) Anderlini P, Donato M, Chan K-W, Huh YO, **Gee AP**, Lauppe MJ, Champlin RE, and Korbling M. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience, Transfusion 39(6), pp 555-560, June 1999.
- 65) Przepiorka D, Lu J-G, Anderlini P, Korbling M, Donato M, Champlin R, **Gee AP** and van Vlasselaer P. Debulking blood stem cell collections by density gradient centrifugation in a closed-vessel system, Cytotherapy, pp 111-117, 1999.
- 66) Lamb LS Jr, Abhyankar SA, Hazlett L, O'Neal W, Folk RS, Vogt S, Parrish RS, Bridges K, Henslee-Downey PJ, and **Gee Adrian P**. (OX-40) on T Cells During the First 100 Days Following Allogeneic Bone Marrow Transplantation as a Marker for Lymphocyte Activation and Therapy-Resistant Graft-Versus-Host Disease, Cytometry (Communications in Clinical Cytometry) 380:238-243 (1999).
- 67) Braunschweig I, Mirza NQ, Rondon G, Lauppe J, Mehra R, Gajewski J, Korbling M. Huh Yo, Geisler D. **Gee AP**, Champlin R, Przepiorka D. High CD34 cell doses do not worsen regimen-related toxicity or early mortality after autologous blood stem cell transplantation for breast cancer. Cytotherapy, Vol. 2, No. 2, pp 105-110, 2000.
- 68) Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, **Gee AP**, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley B, Administration of Neomycin Resistance Gene-marked EBV-specific Cytotoxic T-Lymphocytes as therapy for patients receiving bone marrow transplant for relapsed Hodgkin disease. Human Gene Therapy 2000 Jul 1; 11:1465-1475.
- 69) **Gee AP**. Regulatory issues in cellular therapies. Journal of Cellular Biochemistry. 2002;Suppl 38:104-12
- 70) Salvoldo B, Goss J, Liu Z, Huls Helen M, Doster S, **Gee AP**, Brenner MK, Heslop HE, Rooney CM. Generation of autologous epstein-barr virus-specific cytotoxic t cells for adoptive immunotherapy in solid organ transplant recipients. Transplantation 2001 Sep 27;72(96):1078-86.
- 71) Salvoldo B, Cabbage M, Durett A, Goss J, Huls Helen, Liu Zhensheng, Lopez Teresita, **Gee AP**, Ling P, Brenner M, Heslop H, Rooney C. Generation of EBV-Specific CD4<sup>+</sup> Cytotoxic T Cells from Virus Naïve Individuals<sup>1</sup>. Journal of Immunology.2001.
- 72) **Gee AP**. Mesenchymal stem-cell therapy in a regulated environment. Cytotherapy. 2001;3(5):397-8
- 73) Salvoldo B, Huls Helen M, Zhensheng Liu, Hans-Dieter Volk, Reinke Petra, Sabat Robert, Babel Nina, Jones James F, Webster-Cyriaque Jennifer, **Gee AP**, Brenner Malcolm, Heslop Helen, Rooney Cliona. Adoptive immunotherapy for Chronic Active EBV-infection. Blood 2002.

**Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- 74) **Gee AP.** The impact of regulatory policy on the development of somatic cell therapies in the United States. Transplant Immunology 9(2002) 295-300.
- 75) **Gee AP, Durett AG.** Cell Sorting for therapeutic applications-points to consider. Cytotherapy. 2002;4(1):91-2.
- 76) Savoldo B, Huls MH, Lui Z, Volk HD, Reinke P, Sabat R, Babel N, Jones JF, Webster-Cyriaque J, **Gee AP**, Brenner MK, Heslop HE, Rooney CM. Autologous Epstein-Barr virus (EBV) – Specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood 2002. Vol 100, No.12, 4059-66.
- 77) Z Ye, S Haley, **AP Gee**, PJ Henslee-Downey, LS Lamb Jr. In vitro interactions between  $\gamma\delta$ T cells, DC, and CD4+ T cells; implications for the immunotherapy of leukemia. Cytotherapy. 2002;4(3), 293-304.
- 78) **Gee AP.** What a cell-processing laboratory can and can't do for cellular therapy. Cytotherapy In Press 2002.
- 79) Mehta J, Singhal S, **Gee AP**, Chiang K, Godder K, Rhee F, DeRienzo S, O'Neal W, Lamb L, Henslee-Downey P. Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: single-center experience of 201 patients. Blood 2002 In press.
- 80) HE Heslop, CM Bollard, S Gottschalk, I Kuehnle, MH Huls, **AP Gee**, MK Brenner and CM Rooney. Immune therapy for EBV infections after hemopoietic stem-cell transplant. Cytotherapy 2002;4(5), 433-434.
- 81) Raphael Rousseau, Ann E. Haight, Charlotte Hirschmann-Jax, Eric S. Yvon, Donna R. Rill, Zhuyong Mei, Susan S. Smith, Shannon Inman, Kristine Cooper, Pat Alcoser, Bambi Grilley, **Adrian Gee**, Edwina Popek, Andrew Davidoff, Laura C. Bowman, Malcolm K. Brenner, Douglas Strother. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003;101(5), 1718-726.
- 82) **Adrian Gee.** Manufacturing Cellular Therapy Products in an Academic Facility. BioProcessing Journal. 2003;2(1), 39-43.
- 83) Wagner HJ, Cheng YC, Huls MH, **Gee AP**, Kuehnle I, Krance RA, Brenner MK, Rooney CM, Heslop HE. Prompt versus Pre-emptive Intervention for EBV-Lymphoproliferative Disease. Blood. 2004 Jan 29.
- 84) Mehta J, Singhal S., **Gee AP**, Chiang KY, Godder K, Rhee Fv F, DeRienzo S, O'Neal W, Lamb L, Henslee-Downey PJ. Bone Marrow Transplantation from Partially HLA-Mismatched Family Donors for Acute Leukemia: Single-Center Experience of 201 Patients. Bone Marrow Transplant. 2004 Feb; 33(4), 389-96.
- 85) Rousseau RF, **Gee AP.** Impact of Regulations on Translational Research in Cell and Gene Therapy: The American Experience. Bull Cancer. 2004 Mar;91(3):239-47.
- 86) Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC, Gresik MV, **Gee AP**, Russell HV, Brenner MK, Rooney CM, Heslop HE. Treatment of Nasopharyngeal Carcinoma with Epstein - Barr virus--specific T Lymphocytes. Blood. 2005 Nov 12;105(5): 1898-904

### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- 87) Catherine Bollard, Laura Aguilar, Karin C. Straathof, Benedikt Gahn, M. Helen Huls, Alexandra Rousseau, John Sixbey, M. Victoria Gresik, George Carrum, Melissa Hudson, Dagmar Dilloo, **Adrian Gee**, Malcolm K. Brenner, Cliona M. Rooney, and Helen E. Heslop. Cytotoxic T Lymphocyte Therapy for Epstein - Barr virus Hodgkin's disease. The Journal of Experimental Medicine. 2004 Dec 20. Volume 200, Number 12.
- 88) Lee TC, Savoldo B, Rooney CM, Heslop HE, **Gee AP**, Caldwell Y, Barshes NR, Scott JD, Bristow LJ, O'Mahony CA, Goss JA. Am J Transplant. 2005 Sep; 5(9): 2222-8.
- 89) Rousseau RF, Biagi E, Dutour A, Yvon ES, Brown MP, Lin T, Mei Z, Grilley B, Popek E, Heslop HE, **Gee AP**, Krance RA, Popat U, Carrum G, Margolin JF, Brenner MK. Immunotherapy of High-Risk Acute Leukemia with a Recipient (Autologous) Vaccine Expressing Transgenic Human CD40L and IL-2 After Chemotherapy and Allogeneic Stem Cell Transplantation. Blood. 2005 Oct 25; 107(4): 1332-41.
- 90) Leen AM, Myers GD, Bollard CM, Huls MH, Sili U, **Gee AP**, Heslop HE, Rooney CM. T-Cell Immunotherapy for Adenoviral Infections of Stem-Cell Transplant Recipients. Ann N Y Acad Sci. 2005 Dec; 1062: 104-15.
- 91) Lee TC, Savoldo B, Barshes NR, Rooney CM, Heslop HE, **Gee AP**, Caldwell Y, Scott JD, Goss JA. Use of Cytokine Polymorphisms and Epstein - Barr virus Viral Load to Predict Development of Post-Transplant Lymphoproliferative Disorder in Pediatric Liver Transplant Recipients. Clin Transplant. 2006 May-Jun; 20(3): 389-93.
- 92) Savoldo B, Goss JA, Hammer MM, Zhang L, Lopez T, **Gee AP**, Lin YF, Quiros-Tejeira RE, Reinke P, Schubert S, Gottschalk S, Finegold MJ, Brenner MK, Rooney CM, Heslop HE. Treatment of Solid Organ Transplant Recipients with Autologous Epstein – Barr Virus – Specific Cytotoxic T Lymphocytes (CTLs). Blood. 2006 Jul 11; 108(9): 2942-9.
- 93) Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, Carrum G, Krance RA, Chang CC, Molldrem JJ, **Gee AP**, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Monoculture-derived T Lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med. 2006 Sep 24; 12(10): 1160-6.
- 94) Lee TC, Goss JA, Rooney CM, Heslop HE, Barshes NR, Caldwell YM, **Gee AP**, scott JD, Savoldo B. Quantification of a Low Cellular Immune Response to Aid in Identification of Pediatric Liver Transplant Recipients at High-Risk for EBV Infection. Clin Transplant. 2006 Nov-Dec; 20(6):689-94.
- 95) Bollard CM, Gottschalk S, Leen AM, Weiss J, Straathof KC, Carrum G, Khalil M, Wu MF, Huls MH, Chang CC, Gresik MV, **Gee AP**, Brenner MK, Rooney CM, Heslop HE. Complete Responses of Relapsed Lymphoma Following Genetic Modification of Tumor-Antigen Presenting Cells and T-Lymphocyte Transfer. Blood. 2007 Jul 3.
- 96) Ashford P, Distler P, **Gee AP**, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. ISBT 128 Implementation Plan for Cellular Therapy Products. Transfusion. 2007 Jul; 47(7): 1312-18.
- 97) Ashford P, Distler P, **Gee AP**, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rabe F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. Standards for the Terminology and Labeling of Cellular Therapy Products. Transfusion. 2007 Jul; 47(7): 1319-27.
- 98) Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, Wingard JR, Rowley

**Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- SD, Stroncek D, **Gee AP**, Horowitz MM, Anasetti C. Peripheral Blood Grafts from Unrelated Donors are Associated with Increased Acute and Chronic Graft-Versus Host Disease without Improved Survival. Biol Blood Marrow Transplant. 2007 Dec; 13(12): 1461-8.
- 99) Ashford P, Distler P, **Gee AP**, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rave F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. Terminology and Labeling of Cellular Products: 1. Standards. Bone Marrow Transplant. 2007 Dec; 40(11): 1075-83.
- 100) Ashford P, Distler P, **Gee AP**, Lankester A, Larsson S, Feller I, Loper K, Pamphilon D, Poston L, Rave F, Slaper-Cortenbach I, Szczepiorkowski Z, Warkentin P. Terminology and Labeling of Cellular Products-2: Implementation Plan. Bone Marrow Transplant. 2007 Dec; 40(11): 1085-90.
- 101) Leen AM, Christin A, Khalil M, Weiss H, **Gee AP**, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Identification of Hexon-Specific CD4 and CD8 T-Cell Spitoypes for Vaccine and Immunotherapy. J Virol. 2008 Jan; 82(1): 546-54.
- 102) Harting MT, Baumgartner JE, Worth LL, Ewing-Cobbs L, **Gee AP**, Day MC, Cox Cs Jr. Cell Therapies for Traumatic Brain Injury. Neurosurg Focus. 2008; 24(3-4): E-18. Review.
- 103) **Gee AP**, Sumstad D, Stanson J, Watson P, Proctor P, Kadidlo D, Koch E, Sprague J, Wood D, Styers D, McKenna D, Gallelli J, Griffin D, Read EJ, Parish B, Lindblad R. A Multicenter Comparison Study Between the Endosafe PTS Rapid-Release Testing System and Traditional Methods for Detecting Endotoxin in Cell-Therapy Products. Cytotherapy. 2008;10(4):427-35.
- 104) Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, **Gee AP**, Mei Z, Yvon E, Weiss HL, Liu H, Rooney CM, Heslop HE, Brenner MK. Virus-Specific T Cells Engineered to Coexpress Tumor-Specific Receptors: Persistence and Antitumor Activity in Individuals with Neuroblastoma. Nat Med. 2008 Nov;14(11): 1264-70.
- 105) Reed W, Noga SJ, **Gee AP**, Rooney CM, Wagner JE, McCullough J, McKenna DH, Whiteside TL, Donnenberg AD, Baker AK, Lindblad RW, Wagner EL, Mondoro TH. Production Assistance for Cellular Therapies (PACT): five-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies. Transfusion. 2009; 786-96.
- 106) Harting MT, Cox CS, Day MC, Walker P, **Gee A**, Brennenan MM, Grotta JC, Savitz SI. Bone Marrow-Derived Mononuclear Cell Populations in Pediatric and Adult Patients. Cytotherapy. 2009;11(4):480-4.
- 107) Louis CU, Straathof K, Bollard CM, Gerken C, Huls MH, Gresik MV, Wu MF, Weiss HL, **Gee AP**, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Enhancing the In Vivo Expansion of Adoptively Transferred EBV-Specific CTL with Lymphodepleting CD45 Monoclonal Antibodies in NPC Patients. Blood. 2009 Mar 12;113(11):2442-50.
- 108) Lazarus HM, Kan F, Tarima S, Champlin RE, Confer DL, Frey N, **Gee AP**, Wagner JE, Horowitz MM, Eapen M. Rapid Transport and Infusion of Hematopoietic Cells is Associated with Improved Outcome After Myeloablative Therapy and Unrelated Donor Transplant. Biol Blood Marrow Transplant. 2009 May;15(5): 589-96.
- 109) Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, **Gee AP**, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally Active Virus-Specific T Cells that Target CMV, Adenovirus, and EBV can be Expanded from

### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- Naïve T-Cell Populations in Cord Blood and will Target a Range of Viral Epitopes. Blood. 2009 Aug 27; 114(9): 1958-67.
- 110) Traverse JH, Henry TD, Vaughn DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Piller LB, Penn MS, Byrne BJ, Perin EC, **Gee AP**, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye' LA, Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Rationale and Design for TIME: A Phase II, Randomized, Double-Blind, Placebo-Controlled Pilot Trial Evaluating the Safety and Effect of Timing of Administration of Bone Marrow Mononuclear Cells After Acute Myocardial Infarction. Am. Heart J. 2009 Sep; 158(3): 356-63.
- 111) Collins NH, **Gee AP**, Durett AG, Kan F, Zhang MJ, Champlin RE, Confer D, Eapen M, Howard A, King R, Laughlin MJ, Plante RJ, Setterholm M, Spellman S, Keever-Taylor C, Wagner JE, Weisdorf DJ. The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes. Biol Blood Marrow Transplant. 2009 Oct 9.
- 112) Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, **Gee AP**, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Cytotoxic T Lymphocyte Therapy with Donor T Cells Prevents and Treats Adenovirus and Epstein-Barr Virus Infections After Haploidentical and Matched Unrelated Stem Cell Transplantation. Blood. 2009 Nov 5; 114(19):4283-92.
- 113) Micklethwaite KP, Savoldo B, Hanley PJ, Leen AM, Demmler-Harrison GJ, Cooper LJ, Liu H, **Gee AP**, Schpall EJ, Rooney CM, Heslop HE, Brenner MK, Bollard CM, Dotti G. Derivation of Human T-lymphocytes from Cord Blood and Peripheral Blood with Antiviral and Antileukemic Specificity from a Single Culture as Protection Against Infection and Relapse After Stem Cell Transplantation. Blood. 2010 Jan 28.
- 114) McKenna DH Jr, Adams S, Sumstad D, Sumstad T, Kadidlo D, **Gee AP**, Durett A, Griffin D, Donnenberg A, Amrani D, Livingston D, Lindblad R, Wood D, Styers D. CD34(+) Cell Selection Using Small-Volume Marrow Aspirates: A Platform for Novel Cell Therapies and Regenerative Medicine. Cytotherapy. 2010 Apr; 12(2): 170-7.
- 115) Stroncek D, Berlyne D, Fox B, **Gee AP**, Heimfeld S, Lindblad R, Loper K, McKenna DH Jr, Rooney, CM, Sabatino M, Wagner E, Whiteside T, Wood D, Heath-Mondoro T. Developments in Clinical Cell Therapy. Cytotherapy. 2010 May 12(3): 425-428.
- 116) El Khoury R, Misra V, Sharma S, Cox CS, Walker P, Grotta JC, **Gee A**, Suzuki S, Savitz SI. The Effect of Transcatheter Injections on Cell Viability and Cytokine Release of Mononuclear Cells. AJNR Am J Neuroradiol. 2010 Apr 15; 31(8): 1488-92.
- 117) Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, **Gee AP**, Isola L, Laughlin M, Marks D, Nabhan S, Ruggeri A, Soiffer R, Horowitz MM, Gluckman E, Wagner JE. Effect of Graft Source on Unrelated Donor Haemopoietic Stem-Cell Transplantation in Adults with Acute Leukemia: a Retrospective Analysis. The Lancet. 2010 June.
- 118) Whiteside TL, Griffin DL, Stanson J, Gooding W, McKenna D, Sumstad D, Kadidlo D, **Gee AP**, Durett A, Lindblad R, Wood D, Styers D. Shipping of Therapeutic Somatic Cell Products. Cytotherapy. 2010; 13:201-213.
- 119) Willerson JT, Perin EC, Ellis SG, Pepine CJ, Henry TD, Zhao DX, Lai D, Penn MS, Byrne BJ, Silva G, **Gee A**, Traverse JH, Hatzopoulos AK, Forder JR, Martin D, Kronenberg M, Taylor DA, Cogle CR, Baraniuk S, Westbrook L, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moye LA,

### Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae

- Simari RD; Cardiovascular Cell Therapy Research Network (CCTRN). Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design. Am Heart J. 2010 Aug; 160(2): 215-23.
- 120) **Gee AP**, Richman S, Durett A, McKenna D, Traverse J, Henry T, Fisk D, Pepine C, Bloom J, Willerson J, Prater K, Zhao D, Koç JR, Ellis S, Taylor D, Cogle C, Moyé L, Simari R, Skarlatos S. Multicenter Cell Processing for Cardiovascular Regenerative Medicine applications: The Cardiovascular Cell Therapy Research Network (CCTRN) Experience. Cytotherapy. 2010 Sep; 12(5):684-91.
- 121) Cruz CR, Hanley, PJ, Liu H, Torrano V, Lin YF, Arce JA, Gottschalk S, Savoldo B, Dotti G, Louis CU, Leen AM, **Gee AP**, Rooney CM, Brenner MK, Bollard CM, Heslop HE. Adverse Events Following Infusion of T Cells for Adoptive Immunotherapy a 10-Year Experience. Cytotherapy. 2010 Oct, 12(6):743-9.
- 122) Louis CU, Straathof K, Bollard CM, Ennamuri S, Gerken C, Lopez TT, Huls MH, Sheehan A, Wu MF, Liu H, **Gee A**, Brenner MK, Rooney CM, Heslop HE, Gottschalk S. Adoptive Transfer of EBV-Specific T Cells Results in Sustained Clinical Responses in Patients with Locoregional Nasopharyngeal Carcinoma. J Immunother. 2010 Nov-Dec;33(9):983-90.
- 123) Traverse JH, Henry TD, Vaughan DE, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Simpson LM, Penn MS, Byrne BJ, Perin EC, **Gee AP**, Hatzopoulos AK, McKenna DH, Forder JR, Taylor DA, Cogle CR, Baraniuk S, Olson RE, Jorgenson BC, Sayre SL, Vojvodic RW, Gordon DJ, Skarlatos SI, Moyé LA, Simari RD. LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. Tex Heart Inst J. 2010;37(4): 412-20.
- 124) Bollard CM, Gottschalk S, Huls MH, Leen AM, **Gee AP**, Rooney CM. Good Manufacturing Practice-Grade Cytotoxic T Lymphocytes Specific for Latent Membrane Proteins (LMP)-1 and LMP2 for Patients with Epstein Barr Virus Associated Lymphoma. Cytotherapy. 2011 Mar 1.
- 125) Cox CS Jr, Baumgartner JE, Harting MT, Worth LL, Walker PA, Shah SK, Ewing-Cobbs L, Hasan KM, Day MC, Lee D, Jimenez F, **Gee A**. Autologous Bone Marrow Mononuclear Cell Therapy for Severe Traumatic Brain Injury in Children. Neurosurgery. 2011 Mar; 68(3):588-600.
- 126) Bollard CM, Gottschalk S, Helen Huls M, Leen AM, **Gee AP**, Rooney CM. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma. Cytotherapy 2011 May; 13(5):518-22.
- 127) Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, **Gee AP**, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.
- 128) Passweg JR, Zhang MJ, Rocha V, Kan F, Champlin RE, Isola LM, **Gee AP**, Gibson J, Laughlin MJ, Lazarus HM, Loren A, Marks DI, Gratwohl A, Eapen M. Donor Characteristics Affecting Graft Failure, Graft-versus-Host Disease, and Survival after Unrelated Donor Transplantation with Reduced-Intensity Conditioning for Hematologic Malignancies. Biol Blood Marrow Transplant. 2011 December; 17(12):1869-73.
- 129) Louis CU, Savoldo B, Dotti G, Pule M, Yvon E, Myers GD, Rossig C, Russell HV, Diouf O, Liu E,

### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- Liu H, Wu MF, **Gee AP**, Mei Z, Rooney CM, Heslop HE, Brenner MK. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011 December; 118(23):6050-6.
- 130) Di Stasi A, Tey SK, Doti G, Fujita Y, Kennedy-Nasser A, Martinez C, Straathof K, Liu E, Durett AG, Grilley B, Liu H, Cruz CR, Saboldo B, **Gee AP**, Schindler J, Krance RA, Heslop HE, Spencer DM, Rooney CM, Brenner MK. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011 November; 365(18):1673-83.
- 131) Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, Forder JR, Byrne BJ, Hatzopoulos AK, Penn MS, Perin EC, Baran KW, Chambes J, Lambert C, Raveendran G, Simon DI, Vaughan DE, Simpson LM, **Gee AP**, Taylor DA, Cogle CR, Thomas JD, Silva GV, Jorgenson BC, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Smith DX, Baraniuk S, Piller LB, Loghin C, Aguilar D, Richman S, Zierold C, Betencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moye' LA, Simari RD. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the Late TIME randomized trial. JAMA. 2011 November; 306(19):2110-9.
- 132) Zierold C, Carlson MA, Obodo UC, Wise E, Puazza VA, Meeks MW, Vojvodic RW, Baraniuk S, Henry TD, **Gee AP**, Ellis SG, Moye' LA, Pepine CJ, Cogle CR, Taylor DA. Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale. Am Heart J. 2011 December; 162(6):93-80.
- 133) Sili U, Leen AM, Vera JF, **Gee AP**, Huls H, Heslop HE, Bollard CM, Rooney CM. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant. Cytotherapy. 2012 January; 14(1):7-11.
- 134) Richman S, **Gee AP**, McKenna DH, Traverse JH, Henry TD, Fisk D, Pepine CJ, Bloom J, Willerson JT, Prater K, Zhao D, Koc JR, Anwaruddin S, Taylor DA, Cogle CR, Moye, LA, Simari RD, Skarlatos SI. Factors affecting the turnaround time for manufacturing, testing and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Reserch Network (CCTRN) study. Transfusion. 2012 February; Epub
- 135) Perin EC, Willerson JT, Pepine CJ, Henry TD, Ellis SG, Zhao DX, Silva GV, Lai D, Thomas JD, Kronenberg MW, Martin AD, Anderson RD, Traverse JH, Penn MS, Anwaruddin S, Hatzopoulos AK, **Gee AP**, Taylor DA, Cogle CR, Smith D, Westbrook L, Chen J, Handberg E, Olson RE, Geither C, Bowman S, Francescon J, Baraniuk S, Piller LB, Simpson LM, Loghin C, Aguilar D, Richman S, Zierold C, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012 April; 307(16):1717-26.
- 136) Hanley PJ, Mei Z, da Graca Cabreira-Hansen M, Klis M, Li W, Zhao Y, Durett AG, Zheng X, Wang Y, **Gee AP**, Horwitz EM. Manufacturing mesenchymal stromal cells for phase I clinical trials. Cytotherapy. 2013 Apr;15(4):416-22.
- 137) Traverse JH, Henry TD, Pepine CJ, Willerson JT, Zhao DX, Ellis SG, Forder JR, Anderson RD, Hatzopoulos AK, Penn MS, Perin EC, Chambers J, Baran KW, Raveendran G, Lambert C, Lerman A, Simon DI, Vaughan DE, Lai D, **Gee AP**, Taylor DA, Cogle CR, Thomas JD, Olson RE, Bowman S, Francescon J, Geither C, Handberg E, Kappenman C, Westbrook L, Piller LB, Simpson LM, Baraniuk S, Loghin C, Aguilar D, Richman S, Zierold C, Spoon DB, Bettencourt J, Sayre SL, Vojvodic RW, Skarlatos SI, Gordon DJ, Ebert RF, Kwak M, Moyé LA, Simari RD;



### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- Cardiovascular Cell Therapy Research Network (CCTRN). Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012 Dec 12;308(22):2380-9. Erratum in: JAMA. **2013** Jan 23;309(4):343.
- 138) Leen AM, Bollard CM, Mendizabal AM, Shpall EJ, Szabolcs P, Antin JH, Kapoor N, Pai SY, Rowley SD, Kebriaei P, Dey BR, Grilley BJ, **Gee AP**, Brenner MK, Rooney CM, Heslop HE. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013 Jun 27;121(26):5113-23. doi: 10.1182/blood-**2013**-02-486324. PMID: 23610374
- 139) **Gee AP** How to design a cell or gene therapy clinical trial: Advice from the FDA. Molecular Therapy 2013 21,9, 1-3.
- 140) Cruz CR, Micklethwaite KP, Savoldo B, Ramos CA, Lam S, Ku S, Diouf O, Liu E, Barrett AJ, Ito S, Shpall EJ, Krance RA, Kamble RT, Carrum G, Hosing CM, **Gee AP**, Mei Z, Grilley BJ, Heslop HE, Rooney CM, Brenner MK, Bollard CM, Dotti G. Infusion of donor-derived CD19-redirection virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. **2013** Oct 24;122(17):2965-73.
- 141) Sonpavde G, Wang M, Peterson LE, Wang HY, Joe T, Mims MP, Kadmon D, Ittmann MM, Wheeler TM, **Gee AP**, Wang RF, Hayes TG HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. Invest New Drugs. **2013**

#### **Invited Articles:**

- 1) Kemshead JT, Katz F, Philip T, **Gee AP**: High-dose chemo/radiotherapy and autologous bone marrow rescue for advanced neuroblastoma. Proc 14th Int Cancer Congress, Budapest, 1986.
- 2) **Gee AP**, Graham-Pole J, Lee B, et al: Transplantation for neuroblastoma using immunomagnetically-purged autologous bone marrow - factors influencing engraftment. In: Autologous Bone Marrow Transplantation, ed. K.A. Dicke, M.D. Anderson Hospital and University of Texas, 1987, p.425.
- 3) Graham-Pole JG, **Gee AP**, Gross S, et al: Bone marrow transplantation (BMT) for advanced neuroblastoma (NBL): A multicenter POG pilot study. Advances in Neuroblastoma Research 2:215-223, 1987.
- 4) Boyle MDP, Lawman MJP, **Gee AP**, Young M: Measurement of leukocyte chemotaxis *in vivo*. Methods in Enzymology 162:101-114, 1988.
- 5) Gram-Pole J, Pick T, Casper J, Eifenbein G, **Gee AP**, Graham M, et al: Myeloablative-treatment for children with metastatic neuroblastoma supported by bone marrow infusions progress and problems. Proceedings of the 4<sup>th</sup> International Symposium on Autologous Bone Marrow Transplantation 1989.
- 6) **Gee AP**, Langone JJ: Use of antigen-coated plastic tubes and 125I-labeled Protein A in radioimmunoassay. In: Methods of Enzymology-Immunochemical Techniques, Part E. Academic Press, New York, 1983, Volume 92:403-412.
- 7) **Gee AP**: Titration of components of the classical complement pathway. In: Methods of Enzymology - Immunochemical Techniques, Part F. Academic Press, New York, 93:339-374,

### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

1983

- 8) Minta JO, **Gee AP**: Purification and quantitation of the components of the alternative complement pathway. In: Methods in Enzymology-Immunochemical Techniques, Part F. Academic Press, New York, 93:375-408, 1983.
- 9) **Gee AP**, Moss T, Mansour V, Kulcinski D, Law P, Ishizawa L, Hardwick A.: Large-scale immunomagnetic separation system for the removal of tumor cells from bone marrow. In Advances in Bone Marrow Purging and Processing. Prog Clin Biol Res 377, 181, 1992
- 10) Hardwick, A., Law, P., Mansour, V., Kulcinski, D., Ishizawa, L. & **Gee AP**,: Development of a large-scale immunomagnetic separation system for harvesting CD34-positive cells from bone marrow. In Advances in Bone Marrow Purging and Processing. Prog. Clin. Biol. Res.: 377, 583, 1992.
- 11) Mansour, V., Weiler, M. & **Gee AP**,: Factors limiting the efficiency of immunomagnetic cell separation. In Advances in Bone Marrow Purging and Processing. Prog. Clin. Biol. Res.: 377, 169,1992.
- 12) Civin CI, Trischmann TM, Davis J, Law P, Wiley JM, Noga SJ, Hardwick A, Schepers K, Friedman AD, Hayashi RJ, Kastan MB, Kuerbitz SJ, Leventhal BG, Small D, Fresia A, Ishizawa L, Burgess J, **Gee AP**: Stem Cell Purification and Prospects for Expansion. The Fourth Annual Malnati Symposium, the Biology of Hematologic Malignancies: Implications for Diagnosis and Treatment in the 1990's, Chicago IL.
- 13) Lamb L, Metherell J, Lee C, Brown S, Thompson J, Henslee-Downey PJ, **Gee AP**: Development of an Immunomagnetic Separation Procedure To Deplete  $V\alpha\beta$ -Positive T Cells From Marrow for Use in Partially-Mismatched Related Donor (PMRD) Transplantation. In Advances in Bone Marrow Purging and Processing: Fourth International Symposium. eds. A.P.Gee, S. Gross & D. Worthington-White; Wiley-Liss, Inc. 389:541-550, 1994.
- 14) Lee C, Lamb A, Pati A, Brown S, Thompson J, Parrish R, Henslee-Downey PJ, **Gee AP**: Use of a Closed System for  $V\alpha\beta$ -Positive T Cell Depletion of Marrow for Use in Partially-Mismatched Related Donor (PMRD) Transplantation. Advances in Bone Marrow Purging and Processing: Fourth International Symposium. . eds. A.P.Gee, S. Gross & D. Worthington-White; Wiley-Liss, Inc. 389:523-532, 1994.
- 15) **Gee AP**: Immunologically based methods for the elimination of tumor cells from autologous stem cell grafts. Immunomethods, Dec;5(3):232-42, 1994.
- 16) **Gee AP**: Graft Manipulation-A House of Cards?, J Hematotherapy, 3(1):1-2, 1994.
- 17) **Gee AP**: The corporate influence, J Hematotherapy, Aug;4(4):259-60, 1995.
- 18) **Gee AP**: Purging of Peripheral Blood Stem Cell Grafts. Stem Cells. 13 (Suppl 3): 52-62, 1995.
- 19) Shpall EJ, **Gee AP**, Cagnoni PJ, Hogan C, Gehling U, Hami L, Franklin W, Bearman SI, Ross M, Jones RB: Stem Cell Isolation. Current Opinion in Hematology 2: 452-459, 1995.
- 20) Shpall EJ, **Gee AP**, Cagnoni P, Hogan C, Gehling U, Hami L, Franklin W, Bearman SI, Ross M, Jones RB: Bone Marrow Metastases. In Hematology/Oncology Clinics of North America; W.B. Saunders Co., Phil., PA, 1996, 10:2, 321-343.

## Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae

### Abstracts: (Partial Listing)

- 1) Lamb L., Metherell J, Lee C, Brown S, Thompson J, Henslee-Downey PJ, **Gee AP**: Development of an Immunomagnetic Separation Procedure to Deplete V $\alpha$ 3 Positive T Cells From Marrow for Use in Partially-Mismatched Related Donor (PMRD) Transplantation. September 16-17, 1993; Fourth International Symposium on Bone Marrow Purging and Processing, Orlando, FL.
- 2) Lee C, Lamb L, Pati A, Brown S, Thompson J, Parrish R, Henslee-Downey P J, **Gee AP**: Use of a Closed System V $\alpha$ 3 for Positive T Cell Depletion of Marrow for Use in Partially -Mismatched Related Donor (PMRD) Transplantation. September 16-17, 1993; Fourth International Symposium on Bone Marrow Purging and Processing, Orlando, FL.
- 3) **Gee AP**, Lee C, Lamb L, Pati A, Thompson J, Henslee-Downey PJ: Transplantation of T $\alpha$ 3+ Cell-Depleted Marrow from Partially-Mismatched Related Donors. September 1993; Proceedings of the 1993 International Congress on Bone Marrow Transplantation, Beijing, China.
- 4) **Gee AP**: Purging of Peripheral Blood Progenitor Cell Grafts. November 1993; Peripheral Blood Progenitor Cell Transplantation (PBPCT): Clinical Applications and Economic Considerations. London-Ontario, Canada, November 1993.
- 5) Pati A, Geier S, Parrish R, Godder K, **Gee AP**, Thompson J, Henslee-Downey PJ: Increased Risk Rejection (REJ) Associated with Human Leukocyte-Antigen (HLA) B7 presented as a Foreign Antigen by the Donor Marrow Graft. December 3-7, 1993; Amer Soc of Hemat 35<sup>th</sup> Annual Meeting, St. Louis, MO.
- 6) **Gee AP**, Walker M, King S, Silverman D, Lamb LS: Hematopoietic Stem Cell Graft Evaluation by Multiparameter Flow Cytometric Analysis. September 9-12,1994; Clinical Applications of Cytometry, Charleston, SC.
- 7) Henslee-Downey PJ, **Gee AP**, Godder K, Pati AR, Geier SS, and the Division of Transplantation Medicine: Minimal Risk of Graft Versus Host Disease (GVHD) Following Haploidentical but Partially Mismatched Related Donor (PMRD) Bone Marrow Transplantation (BMT). August 21-25, 1994; 23<sup>rd</sup> Annual Meeting of International Society for Experimental Hematology, Minneapolis, MN.
- 8) Godder K, Henslee-Downey PJ, Pati AR, Lee C, **Gee AP**: Can Patients (PTS) with Refractory Relapsed Acute Leukemia Following Autologous (Auto) Bone Marrow Transplant (BMT) be Salvaged by Allogeneic (Allo) BMT Using a Partially Mismatched Related Donor (PMRD)? August 21-25, 1994; 23<sup>rd</sup> Annual Meeting of International Society for Experimental Hematology, Minneapolis, MN.
- 9) Lamb L, Lee C, **Gee AP**, Geier S, Walker M, Silverman D, Godder K, Pati A, Henslee-Downey PJ: Patterns of Acute Rejection Following Transplantation of Partially Matched Bone Marrow. August 21-25, 1994; 23<sup>rd</sup> Annual Meeting of International Society for Experimental Hematology, Minneapolis, MN.
- 10) **Gee AP**, Holloway W, Ye Z, Walker M, King S, Lee C, Brouillette M, Bowers W, Henslee-Downey PJ: CD34+ Cell Selection from Bone Marrow (BM) for T-Cell Depletion and Dendritic Cell (DC) Purification. December 2-6, 1994; 36<sup>th</sup> Annual Meeting, American Society for Hematology, Nashville, TN.
- 11) Lamb L, Walker M, King S, Best R, Pati A, Godder K, Henslee-Downey PJ, **Gee AP**: Appearance of a Distinct CD8+ Lymphocyte Population Early Following Bone Marrow Transplantation (BMT)

### Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae

- Whose Gradual Acquisition of CD3 is Associated with Reversible Decrease in Peripheral WBC Count. December 2-6, 1994; 36th Annual Meeting, American Society for Hematology, Nashville, TN.
- 12) Lamb L, Walker M, King S, Pati A, Godder K, Henslee-Downey PJ, Mauldin K, Lee C, Brouillette M, **Gee AP**: Flow Cytometric Evaluation of Donor Leukocyte Infusion as Therapy for Relapsed Leukemia Following Allogeneic Partially Matched Related Donor (PMRD) Bone Marrow Transplantation (BMT). September 9-12, 1994; Clinical Applications of Cytometry, Charleston, SC.
  - 13) Abhyankar SH, Godder K, Pati AR, Neglia W, Parrish R, **Gee AP**, Henslee-Downey PJ: Minimal Risk of Acute Graft Versus Host Disease (AGVHD) Following Partially Mismatched Related Donor (PMRD) Marrow Transplants: A Report of 72 Consecutive Patients. March 15-18, 1995; New York Academy of Medical Sciences Conference BMT in the 90's: Into the 21st Century .
  - 14) Ye Z, Syeedur K, Lee C, Bowers W, **Gee AP**: Evaluation of Dendritic Cells in Allogeneic Marrow Grafts. March 10-16, 1995; Keystone Symposium on Molecular & Cellular Biology, Dendritic Cells, Taos, NM.
  - 15) Brouillette M, Lee C, Henslee-Downey PJ, **Gee AP**: Use of Muromonab-CD3 for T-Cell Depletion of Marrow for Use in Partially Mismatched Related Donor Transplantation. June 21-23, 1995; 2nd International Meeting of the International Society for Hematotherapy and Graft Engineering.
  - 16) Lee C, Brouillette M, Mauldin K, Lamb L, Walker M, King S, **Gee AP**, Godder K, Abhyankar S, Henslee-Downey PJ: Defining the Minimum Cell Dose for Peripheral Blood Stem Cell Collections and Transplant. June 21-23, 1995; 2nd International Meeting of the International Society for Hematotherapy and Graft Engineering.
  - 17) Walker M, Lamb LS, Parrish RS, King S, Holloway W, **Gee AP**: Establishment of Immunophenotype Ranges in the Bone Marrow and Blood of Normal Healthy Donors. June 21-23, 1995; 2<sup>nd</sup> International Meeting of the International Society for Hematotherapy and Graft Engineering.
  - 18) Henslee-Downey PJ, Pali AR, Godder K, Abhyankar SH, Mauldin K, Lee C, **Gee AP**: Can Major HLA Mismatched Donor Leukocytes be Given Preemptively to Produce a Graft-Versus-Leukemia Effect Post Bone Marrow Transplant. June 21-23, 1995; 2nd International Meeting of the International Society for Hematotherapy and Graft Engineering.
  - 19) Ye Z, Lee C, Brouillette M, Walker M, King S, **Gee AP**: In Vitro Culture, Characterization & Quantitation of Dendritic Cells in Allogeneic Bone Marrow Grafts. June 21-23, 1995; 2nd International Meeting of the International Society for Hematotherapy and Graft Engineering.
  - 20) Godder K, Pati AR, Abhyankar S, Parrish RS, Neglia WJ, **Gee AP**, Henslee-Downey PJ: Partially Mismatched Related Donor (PMRD) Transplant for Children with Acute Leukemia. October 10-14, 1995; International Society of Paediatric Oncology (SIOP) XXVIIth Meeting.
  - 21) Ye Z, **Gee AP**, Lee C, Turner M, Pali A, Henslee-Downey PJ: Use of Cultured Dendritic Cells (DC) to Generate Cytotoxic T Cells for Immunotherapy of Chronic Myeloid Leukemia (CML). December 1-5, 1995; 37th Annual Meeting of the American Society of Hematology.
  - 22) Abhyankar S, Pati AR, Lamb L, Johnson K, Parrish R, Godder K, **Gee AP**, Henslee-Downey PJ: Cytokine Dysregulation in Donor Leukocyte Infusion (DLI) Induced Acute Graft Versus Host Disease (AGvHD) Following Partially Mismatched Related Donor (PMRD) Bone Marrow Transplant (BMT). December 1-5, 1995; 37th Annual Meeting of the American Society of

## Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae

Hematology.

- 23) Lee C, Henslee-Downey PJ, Brouillette M, Pati A, Godder K, Abhyankar S, **Gee AP**: Comparison of OKT3 and T10B9 for Ex Vivo T-Cell Depletion of Partially Mismatched Related Donor (PMRD) Bone Marrow Transplants (BMT). December 1-5, 1995; 37<sup>th</sup> Annual Meeting of the American Society of Hematology.
- 24) Pati AR, Godder K, Abhyankar S, Parrish R, Lamb L, **Gee AP**, Henslee-Downey PJ: Preemptive Donor Leukocyte Infusions (DLI) to Prevent Relapse in Patients (PTS) with Risk Hematological Malignancies Undergoing Bone Marrow Transplant (BMT) Using Partially Mismatched Related Donors (PMRD). December 1-5, 1995; 37th Annual Meeting of the American Society of Hematology.
- 25) Godder K, Pati AR, Abhyankar S, Lamb L, **Gee AP**, Henslee-Downey PJ: Hemolytic Anemia (HA) is a Common and Treatable Manifestation of Chronic Graft Versus Host Disease (cGvHD) in Patients (PTS) Post Partially Mismatched Related Donor (PMRD) Bone Marrow Transplant (BMT). December 1-5, 1995; 37th Annual Meeting of the American Society of Hematology.
- 26) Ye Z, **Gee AP**, Lee C, Lamb L, Turner M, Pati A, Henslee-Downey PJ: Use of Cultured Human Dendritic Cells (DC) to Induce Chronic Myelogenous Leukemia (CML) - Directed Cytotoxicity in T Lymphocytes to be Used for Therapy of Relapsed CML Post Bone Marrow Transplantation (BMT). January 15-21, 1996; Keystone Symposia on Blood Cell and Bone Marrow Transplants, Keystone, CO.
- 27) Pati A, Henslee-Downey PJ, Godder K, Abhyankar S, Parrish R, Lamb L, Mauldin K, Lee C, **Gee AP**: Donor Leukocyte Infusions (DLI) as Immunotherapy Following Partially Mismatched Related Donor (PMRD) Bone Marrow Transplant (BMT) to Prevent Relapse in High Risk Patients (Pts). January 15-21, 1996; Keystone Symposia on Blood Cell and Bone Marrow Transplants, Keystone, CO.
- 28) Lamb L, Godder K, Parrish R, Turner M, Lee C, Thompson J, Abhyankar S, Pati A, Henslee-Downey PJ, **Gee AP**: Increased Frequency of TCR(αβ) T Cells in Disease-Free Survivors Following Partially Mismatched Related Donor (PMRD) Bone Marrow Transplantation (BMT) for Leukemia. January 16-21, 1996; Keystone Symposia on Blood Cell and Bone Marrow Transplants, Keystone, CO.
- 29) Henslee-Downey PJ, Pati A, Godder K, Abhyankar S, Parrish R, Geier S, Lamb L, Lee C, **Gee AP**: Improved Stable Engraftment Following Partially Mismatched Related Donor (PMRD) T-depleted Bone Marrow Transplant (BMT). UCLA Symposia: Blood Cell and Bone Marrow Transplants, 1996 (submitted).
- 30) **Gee AP**, Ye Z, Lee C, Lamb L, Turner M, Pati A, Henslee-Downey PJ: A Two-Stage Culture System for the Generation of Functional Human Dendritic Cells from CD34+ Marrow Precursors. January 15-21, 1996; Keystone Symposia on Blood Cell and Bone Marrow Transplants, Keystone, CO (accepted and presented).
- 31) Godder K, Pati AR, Abhyankar S, Chiang KY, Hazlett L, Parrish R, **Gee AP**, Henslee-Downey PJ: Update on Second Bone Marrow Transplant Using Partially Mismatched Related Donors as Salvage for Patients with Hematologic Malignancy. March 30, 1996; 25th Annual Meeting of the International Society for Experimental Hematology, New York (submitted).
- 32) Godder K, Pati AR, Abhyankar S, Chiang KY, Hazlett L, **Gee AP**, Henslee-Downey PJ: Partially

### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- Mismatched Related Donors Allow for Early Allogeneic Transplant Intervention and Improved Disease Free Survival in Young Patients with Poor Risk Acute Leukemia. October 10-12, 1996; Ninth Annual Meeting of the American Society of Pediatric Hematology/Oncology, Chicago, IL.
- 33) Godder K, Pati AR, Abhyankar SH, Chiang KY, Hazlett L, Parrish R, **Gee AP**, Henslee-Downey PJ: Second Bone Marrow Transplant (BMT) as Salvage For Patients with Hematologic Malignancies Using Partially Mismatched Related Donors (PMRD). October 26-28, 1996; 3rd International Symposium: Impact of Cancer Biotechnology Diagnostic & Prognostic Indicators, Nice, France.
- 34) Pati AR, Godder SH, **Gee AP**, Henslee-Downey PJ: Cyclosporine-induced autologous graft-versus-host disease following autologous blood stem cell transplantation for lymphoma. July 20, 1995; Bone Marrow Transplantation (1996) 17:1081-1083.
- 35) Arpacı F, **Gee AP**, Brouillette M, Lee C, Glover L, Holloway W, Zhang C, Henslee-Downey PJ: Controllable T-Cell Depletion of Marrow by High Gradient Magnetic Separation. August 23-27, 1996; 25<sup>th</sup> Meeting of the International Society for Experimental Hematology.
- 36) Lamb LS, **Gee AP**, Parrish RS, Lee C, Walker M, Geier S, Harris G, Pati A, Godder K, Henslee-Downey PJ: Acute rejection of marrow grafts in patients transplanted from partially mismatched related donor: clinical and immunologic characteristics. June 14, 1995; Bone Marrow Transplantation (1996) 17:1021-1027.
- 37) **Gee, AP:** Peripheral Blood Progenitor Cell Transplants -The End of BMT? 1995; The Canadian Red Cross and the Canadian Blood Transfusion Society, Edmonton, Canada.
- 38) **Gee, AP:** Peripheral Stem Cell Collection and Manipulation. May 23-26, 1996; Canadian Society of Transfusion Medicine, Canadian Red Cross Society Conference, Toronto, Ontario, Canada.
- 39) **Gee, AP:** The History of Regulation of Stem Cells. October 12-16, 1996; American Society of Blood Banks.
- 40) **Gee, AP:** Positive Selection, Negative Selection and the Search for the Elusive Stem Cell. October 12-16, 1996; American Association of Blood Banks, Orlando, Florida.
- 41) **Gee, AP:** Walking the Tight Rope, Cook Fort Worth Children's Hospital. November 7, 1996; Fort Worth, Texas.
- 42) **Gee, AP:** Pediatric Bone Marrow Transplantation. January 1997; Transplantation and the Food and Drug Administration, Ft. Lauderdale, FL.
- 43) **Gee, AP:** Pediatric Bone Marrow Transplantation. January 1997; T Cell Depletion Technology, Ft. Lauderdale, FL.
- 44) **Gee, AP:** Regulation without Fossilization, International Symposium on Applications of Flow Cytometry in Stem Cell Transplantation. April 1997; Stem Cell Graft Engineering, Atlanta, GA.
- 45) **Gee, AP:** Graft Engineering - What have we learned? April 1997; 5<sup>th</sup> International Symposium on Stem Cell Transplantation. San Diego, CA.
- 46) McGuirk J, Godder K, Pati AR, Abhyankar S, Chiang KY, Lee CG, Hazlett L, Parrish R, **Gee AP**, Henslee-Downey PJ: Salvage of relapsed acute myelogenous leukemia post-transplant using a partially mismatched related donor for second bone marrow transplant. December 6-10, 1996; 38th Annual Meeting, Orlando, Florida.

**Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- 47) McGuirk J, Godder K, Pati AR, Abhyankar S, Chiang KY, Hazlett L, Parrish R, **Gee AP**, Henslee Downey PJ: Relapse of acute myelogenous leukemia (AML) following bone marrow transplant (BMT) can be salvaged with a second BMT using a partially mismatched related donor. October 2-6, 1-996; ASBMT/AACR Meeting, San Diego, CA.
- 48) Abhyankar S, Pati AR, Johnson K, Hazlett L, Parrish R, Jackson L, Godder K, **Gee AP**, Henslee-Downey PJ: Serum cytokine levels in cyclosporine-induced graft versus hosts disease following autologous blood stem cell transplant. December 6-10, 1996; 38th Annual Meeting, Orlando, FL.
- 49) Ye Z, Lamb L, **Gee AP**: Stimulation of T Cell Proliferation and Alloreactivity by Culture Dendritic Cells. Keystone Symposia Feb 1, 1997; Colorado.
- 50) Abhyankar S, Godder K, Chiang KY, Pati AR, Hazlett L, Parrish R, **Gee AP**, Henslee-Downey PJ: Low risk of Graft Failure and Graft Versus Host Disease Partially Mismatched Related Donor Bone Marrow Transplant for Marrow Failure and Preleukemia Syndromes in Children. January 23-25, 1997; Marrow Transplantation in Children, Ft. Lauderdale, FL.
- 51) Godder K, Abhyankar S, Chiang KY, Pati AR, Hazlett L, Parrish R, **Gee AP**, Henslee-Downey PJ: Long Term Survival in Pediatric Patients with Advanced Acute Myelogenous Leukemia is Feasible when Using Partially Mismatched Related Donors Bone Marrow Transplantation. January 23-25, 1997; Marrow Transplantation in Children, Ft. Lauderdale, FL.
- 52) Chiang KY, Godder K, Abhyankar S, Pati AR, Hazlett L, Parrish R, Lee C, **Gee AP**, Henslee-Downey PJ: Revisit of Allogeneic Bone Marrow Transplantation for Childhood Acute Lymphoblastic Leukemia: Experience of Partially Mismatched Related Donor Transplantation. January 23-25, 1997; Marrow Transplantation in Children, Ft. Lauderdale, FL.
- 53) Lamb LS, Henslee-Downey PJ, Parrish RS, Turner MW, King SM, Fisher S, **Gee AP**: Overview of the Role of Flow Cytometry in BMT: Graft Evaluation, Immunophenotyping, and Functional Monitoring. April 3-5, 1997; Applications of Flow Cytometry in Blood and Marrow Stem Cell Transplantation, Stone Mountain, GA.
- 54) **Gee AP**: Stem Cell Graft Engineering-Regulation Without Fossilization. April 3-5, 1997; Applications of Flow Cytometry in Blood and Marrow Stem Cell Transplantation, Stone Mountain, GA.
- 55) Henslee-Downey PJ, Lee CG, Hazlett LJ, Pati AR, Godder KT, Abhyankar SH, McGuirk JP, Christiansen NP, Parrish RS, Lamb LS, **Gee AP**: Rare failure to engraft following haploidentical T-cell depleted marrow transplantation using enhanced host immunoablation and OKT3 graft purging. August 24-28, 1997; 26<sup>th</sup> Annual Meeting of the International Society for Experimental Hematology, Cannes, France.
- 56) Abhyankar S, Christiansen N, Godder K, Chiang KY, McGuirk J, Lee C, **Gee A**, Parrish R, Hazlett L, Bridges K and Henslee-Downey PJ. Partially mismatched related donor bone marrow transplant (PMRD BMT) for chronic myeloid leukemia (CML) in first chronic phase. Blood Suppl 1, 90:107a-, 1997.
- 57) Ye Z, **Gee AP**, Lamb L, Harris G, Lee C, Reiser B, Henslee-Downey PJ and Rich I. Generation and purification of a large number of CD11C+ DC from human marrow CD34+ cells for immunotherapy. Blood Suppl 1, 90:367a-, 1997.

**Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- 58) Keever-Taylor CA, Collins NH, Carter S, Kelley L, **Gee A** and Fuller S. Report on the standardization of clonogenic hematopoietic precursor assays for the unrelated donor bone marrow transplantation trial. Blood Suppl 1, 90:368a-, 1997.
- 59) Kornblau Sm, Marini FC, Snell V, Lu J, **Gee A**, Durrett A and Przepiorka D. Production of human suicidal lymphocytes induces variable changes in lymphocyte subset composition (LSC): Potential implications for gene therapy trials. Blood Suppl 1, 90:421b-, 1997.
- 60) Alyea P, Canning CM, Houde H, Soiffer RJ, Giralt S, Webb IJ, Donovan J, **Gee A**, Gribben J, Champlin R, Atkinson K. A Pilot Study of CD8+ Cell Depletion of Donor Lymphocyte Infusions (DLI) Using CD8 Monoclonal Antibody Coated High Density Microparticles (HDM). Blood Suppl 1, 94:161a, 1999.
- 61) Liu Z, Wilson JM, Jones MC, Khan SP, Krance RA, Brenner MK, Rooney CM, Heslop H, **Gee AP**. Addition of B Cell Depletion of Donor Marrow with Anti-CD20 Antibody to a T Cell Depletion Regimen for Prevention of EBV Lymphoma After Bone Marrow Transplant. Blood Suppl 1, 94:638a, 1999.
- 62) Madaani F, Olivarez E, Annandale K, Lauppe MJ, Walker J, Durett A, Champlin RE, **Gee AP**. Selective Loss of CD34+ Cells During Separation of Platelets From Mobilized PBSC. Blood Suppl 1, 92:118a, 1998.
- 63) Anderlini P, Donato M, Lauppe J, Huh YO, **Gee A**, Champlin R, Korbling M. Allogeneic Blood Stem Cell Collection: 4-Year Results of the M.D. Anderson Protocol in Normal Donors. Blood Suppl 1, 92:120a, 1998.
- 64) Lamb LS, **Gee AP**, Musk P, O'Hanlon TP, Hazlett LJ, Geier SS, Folk RS, Harris WG, McPherson K, Parrish Rs, Lee C, Henslee-Downey PJ. Influence of T Cell Depletion Method on Circulating T Cell Reconstitution and Potential Role in the Graft Versus Leukemia Effect. Blood Suppl 1, 92:492a, 1998.
- 65) Braunschweig I, Przepiorka D, Mirza NQ, Rondon G, Mehra R, Gajewski J, Korbling M, Lauppe J, **Gee A**, Champlin R. Toxicity and Early Mortality After Autologous Blood Stem Cell Transplantation for Breast Cancer is Independent of CD34+ Cell Dose. Blood Suppl 1, 92:275a, 1998.
- 66) **Gee AP**, Durett A, Thomas MW, Walker JA, Champlin RE, Gajewski JL. Preparation of T-Cell Depleted Megadose Stem Cell PBPC Grafts for HLA-Mismatched Transplantation. Blood Suppl 1, 92:650a, 1998.
- 67) Durett AG, Champlin RE, **Gee AP**. Distribution of AC133+ Cells During G-CSF Mobilization of CD34+ Cells In Normal Donors. Blood Suppl 1, 92:682a, 1998.
- 68) Durrett AG, Brenner M, **Gee A**. Selective Destruction of Lineage Negative CD34 Cells by Lysing Agents Used for Flow Cytometry. ISHAGE Meeting, San Diego, CA, June 2000 (in press).
- 69) Durett A, Wilson J, Newsom B, Schwab G, Havrilla N, Brenner M, Heslop H and **Gee A**. Alloactivation of T Cells is Associated With Increased Binding of ABX-CBL an Anti-CD147 Monoclonal Antibody - A New Target for T Cell Depletion. ISHAGE Meeting, San Diego, CA, June 2000 (in press).
- 70) Wilson JM, Lee C, Liu Z, Khan SP, Krance RA, Brenner MK, Rooney CM, Heslop HE, and **Gee AP**. Prevention of EBV Lymphoma After Bone Marrow Transplant by the Addition of Anti-CD20 to T Cell Depletion of the Graft. ISHAGE Meeting, San Diego, CA, June 2000 (in press).



**Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- 71) Heslop H, Rooney C, Brenner M, Krance R, Carrum G, Gahn B, Bollard C, Khan S, **Gee A**, Popat U, Gresik M, Przepiorka D, Kuehnle I, Grilley B. Administration of Neomycin Resistance Gene-Marked EBV-Specific Cytotoxic T-Lymphocytes as Therapy for Patients Receiving a Bone Marrow Transplant for Relapsed EBV-Positive Hodgkin Disease. Human Gene Therapy 11:1465-1475 (July 1, 2000).
- 72) Bollard C, Gahn B, Aguilar L, Huls M, Gresik M, **Gee AP**, Brenner M, Rooney C, Heslop H. Cytotoxic T Lymphocyte Therapy for EBV+Hodgkin Disease. Blood Vol 96:2475 (Nov 2000).
- 73) Wilson J, Lee C, Liu Z, Khan S, Krance R, Brenner M, Rooney C, Heslop H, **Gee AP**. Prevention of EBV Lymphoma after BMT by the addition of Anti-CD20 to T-cell depletion of the graft. Cytotherapy Vol 2 Num 4:321 (2000).
- 74) Durett A, Wilson J, Newsom B, Schwab G, Havrilla N, Brenner M, Heslop H, **Gee AP**. Alloactivation of T cells is associated with increased binding of ABX-CBL, an anti-CD147 MAB – A new target for T-cell depletion? Cytotherapy Vol 2 Num 4:338 (2000).
- 75) Durett A, Brenner M, **Gee AP**. Selective destruction of lineage negative CD34 cells by lysing agents used for flow cytometry. Cytotherapy Vol 2 Num 4:342 (2000).
- 76) Hans-Joachim Wagner, Yee C Cheng, Zhensheng Liu, Barbara Savoldo, Helen M Huls, **Adrian P Gee**, Helen E Heslop, Cliona M Rooney. Monitoring of transplanted patients at risk of Epstein-Barr virus (EBV)-induced lymphoproliferative disorder (LPD) by real time PCR quantification of EBV DNA in peripheral blood. The 43<sup>rd</sup> ASH Annual Meeting (2001).
- 77) Liu Z, Savoldo B, Huls H, Lopez T, **Gee A**, Wilson J, Brenner MK, Heslop HE, Rooney CM. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas. Recent Results Cancer Res 2002;159: 123-33.
- 78) Ye Zhou, Haley Stephen, **Gee AP**, Henslee-Downey Jean, Lamb Lawrence. In Vitro Interactions between T cells, Dendritic cells, and CD4+ T cells; Implications for Immunotherapy of Leukemia. Immunobiology 2002
- 79) Savoldo B, Cabbage M, Durett A, Goss J, Huls H, Liu Z, Lopez T, **Gee A**, Ling P, Brenner M, Heslop H, Rooney C. Generation of EBV-Specific CD4<sup>+</sup> Cytotoxic T Cells from Virus Naïve Individuals<sup>1</sup> The Journal of Immunology, 2002, 168: 909-918.
- 80) R. Rousseau, E Biagi, E Yvon, Z Mei, S Inman, D Rill, H Heslop, U Popat, **A Gee**, R Krance, G Carrum, P Alcoser, S Rodgers, I Kuehnle, J Margolin and M Brenner. Treatment of High-Risk Acute Leukemia with An Autologous Vaccine Expressing Transgenic IL-2 and CD40L. ASH 2002.
- 81) Leen AM, Myers GD, Bollard CM, Huls MH, Sili U, **Gee AP**, Heslop HE, Rooney CM. T-cell immunotherapy for adenoviral infections of stem-cell transplant recipients. Ann N Y Acad Sci. 2005 Dec; 1062:104-15.

## Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae

### Books/Chapters:

- 1) **Gee AP**: Immunological studies on whole-body hyperthermia treatment for advanced cancer. Ph.D. Thesis, University of Edinburgh, Edinburgh, Scotland, 1977.
- 2) **Gee AP**, Williams AE, Pettigrew RT, Smith AN: The effects of whole-body hyperthermia treatment on the general immunocompetence of the advanced cancer patient. In Cancer Therapy by Hyperthermia and Radiation. Urban and Schwarzenberg, Baltimore, 1978, pp 312-315.
- 3) Ellssel J, Pettigrew RT, **Gee AP**, Smith AN: Effect of whole body hyperthermia (41.8°C) on carcinoembryonic antigen values in advanced and malignancy - preliminary results. In Cancer Therapy by Hyperthermia and Radiation. Urban and Schwarzenberg, Baltimore, 1978, pp 316-317.
- 4) Pettigrew RT, Ludgate CM, **Gee AP**, Smith AN: Whole-body hyperthermia combined with chemotherapy in the treatment of advanced human cancer. In Cancer Therapy by Hyperthermia and Radiation. Urban and Schwarzenberg, Baltimore, 1978, pp.337-339.
- 5) **Gee AP**, Gross S (editors): Proceedings of the First International Workshop on Bone Marrow Purging. Bone Marrow Transplantation, 2, Suppl. 2, 1987.
- 6) **Gee AP**: Monoclonal antibodies as agents to purge tumor cells from bone marrow. Laboratory & Clinical Experiences. In: Pediatric Tumors: Immunological & Molecular Markers, ed. Kemshead J. CRC Press, Boca Raton, FL. 1989, pp 105-124.
- 7) **Gee AP**: Bone marrow purging and processing: A review of ancillary factors. In: Progress in Clinical & Biological Research, 333, pp.507-522, 1990.
- 8) Gross S, **Gee AP**, Worthington-White D (editors): Bone Marrow Purging & Processing. Progress in Clinical & Biological Research, 333, Wiley-Liss, New York, 1990.
- 9) **Gee AP**, Graham-Pole J: Use of bone marrow purging and bone marrow transplantation. In: Neuroblastoma: Tumor Biology and Treatment, ed. Pochedly C, CRC Press, Boca Raton, Florida, pp.317-334, 1990.
- 10) Lawman MJP, **Gee AP**, Lawman PD, Boyle MDP: Measurement of in vivo leukocyte chemotaxis using Fc-binding proteins. In Bacterial Fc-binding proteins, ed. Boyle MDP, Academic Press, Orlando, 1990, pp405-416.
- 11) Boyle MDP, Lawman MJP, **Gee AP**: Application of Fc-binding proteins for the detection of specific antibodies. In: Bacterial Fc-binding proteins. pp. 181-196 ed. Boyle MDP, Academic Press, Orlando, 1990.
- 12) **Gee AP** (editor): Bone Marrow Processing & Purging - a practical guide. CRC Press, Boca Raton, 1991.
- 13) **Gee AP**, Hardwick AH, Mansour VH, et al: Pre-clinical studies on bone marrow manipulation. In Magnetic Separation Techniques Applied to Cellular & Molecular Biology, ed. Kemshead JT; Wordsmiths Conference Publications, 1991, pp119-129.
- 14) **Gee AP**: Quality control in bone marrow processing in Bone Marrow Processing and Purging, ed. Gee AP, CRC Press, Boca Raton, FL, 1991, pp 19-27.
- 15) Worthington-White D, **Gee AP**, Gross S: Bone Marrow Purging & Processing. Progress in

### **Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

Clinical & Biological Research, 377, Wiley-Liss, New York, 1992 .

- 16) **Gee AP**, Lee CE, Gross S, Graham-Pole J: Immunomagnetic purging of neuroblastoma cells from autologous bone marrow. In Bone Marrow and Stem Cell Processing - A manual of current techniques, eds. Areman E, Deeg HJ, Sacher RA; F.A. Davis Co., Philadelphia, PA. 1992, pp 267-274.
- 17) **Gee AP**: Malignant cell purging - Immunophysical techniques: In Stem Cell and Marrow Processing for Transplantation, eds. Lasky L, Warkentin P; American Association of Blood Banks, Bethesda, MD, p 83, 1994.
- 18) Collins NH, **Gee AP**, Henslee-Downey PJ: T cell depletion of allogeneic bone marrow transplants by immunologic and physical techniques. In Stem Cell and Marrow Processing for Transplantation, eds. Lasky L, Warkentin P; American Association of Blood Banks, Bethesda, MD., 1994.
- 19) **Gee AP**, Lamb LS: Preparation of Samples for Flow Cytometric Analysis of Progenitor Cells. Hematopoietic Stem Cells: The Mulhouse Manual, Alpha Med Press, Dayton, OH, pp67-78, 1994.
- 20) **Gee AP**, Gross S, Worthington-White D (editors): Advances in Bone Marrow Purging and Processing: Fourth International Symposium. Wiley-Liss, Inc. Vol. 389, 1994.
- 21) Kemshead J, **Gee AP**: Bone Marrow Purging. In Color Atlas and Text of Bone Marrow Transplantation, eds. Treleaven J, Wiernik P; Mosby-Wolfe, pp. 117-128, 1995.
- 22) **Gee AP**: Immunomagnetic Cell Separation Using Antibodies and Super Paramagnetic Microspheres. In Cell Separation Methods and Applications, ed. Recktenwald D; Marcel Dekker Inc. 1996 (in press).
- 23) **Gee AP**: Antibody and complement-mediated cell separation. In Cell Separation Methods and Applications, ed. D. Recktenwald; Marcel Dekker Inc., 1998 (in press).
- 24) **Gee AP**: Purging Tumor From Autologous Stem Cell Grafts in The Clinical Practice of Stem Cell Transplantation, eds. Barrett J, Treleaven J, 1998.
- 25) **Gee AP**: Regulation of Hematopoietic Progenitor Cell Therapy in Bone Marrow Transplantation, eds. Lister J, Ball ED, 1998.
- 26) **Gee AP**: Collection and Processing of Peripheral Blood Hematopoietic Progenitor Cells in Blood Stem Cell Transplantation, Reiffers J, Goldman J, Armitage J, 1998.
- 27) **Gee AP**: T Cell Depletion of Stem Cell Grafts in The Clinical Practice of Stem Cell Transplantation, eds. Barrett J, Treleaven J, 1998.
- 28) **Gee AP**: Peripheral Blood Stem Cell Mobilization, Collection and Processing in Bone Marrow Transplantation, eds. Lister J, Ball ED, 1998.
- 29) **Gee AP**: Tumor Purging Technologies: More Questions Than Answers. In: Autologous Blood and Marrow Transplantation, IX, ed. Dicke KA and Keating A, Carden Jennings Publishing, pp. 541-550, 1999.

**Adrian Philip Gee, M.I.Biol, Ph.D. Curriculum Vitae**

- 30) **Gee AP:** Lamb LS: Enumeration of CD34-Positive Hematopoietic Progenitor Cells in Immunophenotyping, eds. Stewart C and Nicholson J; Wiley-Liss, Inc., 2000.
- 31) **Gee, AP:** Challenges in Autologous Graft Manipulation. In: Autologous Blood and Marrow Transplantation, X, ed Dicke KA and Keating A, Carden Jennings Publishing, pp. 19-29, 2001.
- 32) **Gee AP:** The impact of regulation on cellular and gene therapy. Clinical Bone Marrow and Blood Stem Cell Transplantation Third Edition. Eds. Atkinson K, Brenner M, Champlin R, Fibbe W, Ljungman P, Ritz J. pp. 457-465 Cambridge University Press 2004.
- 33) **Gee AP:** cGMP Facilities and Manufacturing. Cell Therapy. Ed: Gee AP. Springer 2009.
- 34) **Gee AP:** GMP Facility Design: Baylor College of Medicine *in* **Gee AP:** cGMP Facilities and Manufacturing. Cell Therapy. Pp67-78. Ed: Gee AP. Springer 2009.
- 35) **Gee AP;** Design of a new GMP facility – lessons learned *in* **Gee AP:** cGMP Facilities and Manufacturing. Cell Therapy. Pp 79-86 Ed: Gee AP. Springer 2009.
- 36) **Gee AP,** Lyon DL: Cleaning procedures *in* **Gee AP:** cGMP Facilities and Manufacturing. Cell Therapy. Pp135-144 Ed: Gee AP. Springer 2009.
- 37) **Gee AP,** Rooney CM: Supply management *in* **Gee AP:** cGMP Facilities and Manufacturing. Cell Therapy. Pp 157-170Ed: Gee AP. Springer 2009.
- 38) **Gee AP,** Lyon DL: Environmental monitoring *in* **Gee AP:** cGMP Facilities and Manufacturing. Cell Therapy. Ed: pp 145-156 Gee AP. Springer 2009.
- 39) **Gee AP:** Product manufacturing *in* **Gee AP:** cGMP Facilities and Manufacturing. Cell Therapy. Pp 199-214 Ed: Gee AP. Springer 2009.
- 40) **Gee AP:** Graft Engineering and cell processing *in* Hematology: Basic principles and practice. EdHoffman R, Benz E, Shattil S, Furie B, Silberstein L, McGlave P, Heslop H. Churchill Livingstone 2009.